https://www.pharmaradar360.com hourly 1 https://www.pharmaradar360.com/news hourly 0.95 https://www.pharmaradar360.com/regulators daily 0.9 https://www.pharmaradar360.com/trials daily 0.85 https://www.pharmaradar360.com/pipeline daily 0.9 https://www.pharmaradar360.com/drug-approvals daily 0.9 https://www.pharmaradar360.com/journals weekly 0.8 https://www.pharmaradar360.com/pharma-companies weekly 0.8 https://www.pharmaradar360.com/specialties weekly 0.8 https://www.pharmaradar360.com/sources weekly 0.8 https://www.pharmaradar360.com/newsrooms weekly 0.8 https://www.pharmaradar360.com/pharma-tools weekly 0.8 https://www.pharmaradar360.com/pharma-communities weekly 0.75 https://www.pharmaradar360.com/pro weekly 0.75 https://www.pharmaradar360.com/tools weekly 0.7 https://www.pharmaradar360.com/about monthly 0.5 https://www.pharmaradar360.com/privacy yearly 0.35 https://www.pharmaradar360.com/support monthly 0.35 https://www.pharmaradar360.com/disclaimer yearly 0.35 https://www.pharmaradar360.com/drug/pembrolizumab daily 0.9 https://www.pharmaradar360.com/drug/semaglutide daily 0.9 https://www.pharmaradar360.com/drug/tirzepatide daily 0.9 https://www.pharmaradar360.com/drug/trastuzumab-deruxtecan daily 0.9 https://www.pharmaradar360.com/drug/osimertinib daily 0.9 https://www.pharmaradar360.com/drug/nivolumab daily 0.9 https://www.pharmaradar360.com/drug/dupilumab daily 0.9 https://www.pharmaradar360.com/drug/risankizumab daily 0.9 https://www.pharmaradar360.com/drug/lecanemab daily 0.9 https://www.pharmaradar360.com/drug/atezolizumab daily 0.9 https://www.pharmaradar360.com/article/pharma-pulse-vicapsys-stateline-merger-and-veritiv-s-tempsafe-rxshield-741f22ac71864ee7 2026-09-24T15:59:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/xlv-vs-ibb-how-healthcare-diversification-compares-to-biotech-concentration-4b45fd335a5f66c4 2026-09-24T15:57:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/erlc-calls-for-stronger-fda-protections-on-mifepristone-58d8b71863d1edc6 2026-09-24T15:57:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/taro-pharmaceutical-industries-stock-faces-a-legal-settlement-b82bcea56e890817 2026-09-24T15:47:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/decision-orphan-registered-medicinal-products-99fb5dd11a1ac4aa 2026-09-24T15:45:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-eli-lilly-s-psychedelic-investment-could-mean-for-the-emerging-field-1631e12377162d46 2026-09-24T15:37:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/kobayashi-pharmaceutical-receives-take-private-proposal-from-japan-uk-fund-conso-cf4425fbc6c8fdc0 2026-09-24T15:35:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/atyr-pharma-aligns-with-fda-on-phase-3-trial-design-for-sarcoidosis-drug-efzofit-7e1f399d800d3373 2026-09-24T15:29:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/fidelity-healthcare-etf-fhlc-vs-vaneck-biotech-etf-bbh-which-fund-is-the-better-36084fc467c759f7 2026-09-24T15:10:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/marinomed-biotech-ag-mari-operations-ordered-closed-f5cdc1e3765a0c59 2026-09-24T15:08:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/sourcing-the-next-blockbuster-big-pharma-banks-on-chinese-biotech-1b18adbe7944c5f1 2026-09-24T15:06:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/1-900-bottles-of-thyroid-pills-trigger-fda-s-top-alert-fc4b286a0c33caeb 2026-09-24T15:03:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/pro-life-groups-ask-fda-to-restore-abortion-pill-safeguards-704a0ff085fc32d2 2026-09-24T15:01:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/cspc-pharmaceutical-says-phase-iii-trial-of-becotatug-achieves-positive-topline-45ba1ec5b8d7169f 2026-09-24T15:01:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/dhsc-senior-officials-business-expenses-hospitality-and-meetings-april-to-june-2-7d9da5047a679d1e 2026-09-24T15:00:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/dhsc-senior-officials-business-expenses-hospitality-and-meetings-a328912eb87631b3 2026-09-24T15:00:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/dhsc-special-advisers-gifts-hospitality-and-meetings-april-to-june-2026-3dd02564ad41de97 2026-09-24T15:00:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/dhsc-special-advisers-gifts-hospitality-and-meetings-52d34624ad3609c5 2026-09-24T15:00:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/dhsc-ministerial-gifts-hospitality-overseas-travel-and-meetings-2332d5d2f3822f2e 2026-09-24T15:00:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/dhsc-ministerial-travel-and-meetings-april-to-june-2026-99b9b0a66353fa3e 2026-09-24T15:00:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/dhsc-business-appointment-rules-advice-april-to-june-2026-6e8c1aef13dcf8a5 2026-09-24T15:00:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/dhsc-business-appointment-rules-advice-3b5125a476d37863 2026-09-24T15:00:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/dr-heidi-overton-appears-before-senate-committee-for-confirmation-hearing-as-nex-927f5ad766e1ef04 2026-09-24T14:53:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/fidelity-healthcare-etf-fhlc-vs-vaneck-biotech-etf-bbh-which-fund-is-the-better-79716d464d0ab893 2026-09-24T14:45:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-policy-in-motion-continued-the-trump-administration-s-second-wave-9ef8298908d47403 2026-09-24T14:36:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/high-consequence-infectious-disease-country-specific-risk-11ed7e663ad962ce 2026-09-24T14:30:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-and-marburg-haemorrhagic-fevers-outbreaks-and-case-locations-16b29cdb0bb31831 2026-09-24T14:30:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/outbreaks-under-monitoring-in-2026-eb6ae222898106b1 2026-09-24T14:30:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/7-breast-cancer-clinical-trials-currently-enrolling-in-the-us-cec940f5bea5ba71 2026-09-24T14:28:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/vaccine-update-30d4e36f5ec7eb5a 2026-09-24T14:26:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-ai-agents-need-regulatory-guardrails-5c84bf499aa76f81 2026-09-24T14:17:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/watch-live-senators-question-heidi-overton-in-confirmation-hearing-for-fda-commi-1cdb413fdff776b1 2026-09-24T14:06:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-market-europe-september-2026-4bdbac2b14a27119 2026-09-24T14:05:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-s-henlius-carves-out-440m-t-cell-engager-deal-with-amberstone-228b047b6c3cadb1 2026-09-24T14:02:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-biotech-has-a-lot-riding-on-trump-s-fda-pick-7b6780f9008f70f9 2026-09-24T13:58:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/kyverna-s-cell-therapy-shows-lasting-autoimmune-benefit-2450aa478dccce91 2026-09-24T13:54:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/acadia-misses-mark-in-alzheimer-s-but-concludes-phase-3-absolutely-worth-pursuin-182796a9f2f9775e 2026-09-24T13:46:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/panel-will-weigh-overton-s-fda-public-health-direction-e565fb64fbc05ab4 2026-09-24T13:42:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/otsuka-jv-recalls-one-lot-of-sodium-chloride-over-labeling-issue-efc8c0c36d286f61 2026-09-24T13:41:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/5-things-to-know-in-life-sciences-week-of-sept-21-2026-06f05da46e262ef6 2026-09-24T13:32:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/non-animal-safety-tests-gain-a-new-place-in-fda-drug-rules-but-animal-studies-ar-30132ac08a5c623a 2026-09-24T13:31:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/students-take-first-steps-toward-biotech-careers-5ccf576365171d58 2026-09-24T13:25:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/organisation-testing-registration-record-of-combo-rapid-lfd-test-users-b084323e6e76370d 2026-09-24T13:17:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/combined-covid-19-and-flu-tests-use-in-ari-outbreaks-in-adult-social-care-homes-81119bdf4cea369a 2026-09-24T13:14:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/australia-starts-investigation-into-openai-medicare-breach-a86a3687e693513c 2026-09-24T13:10:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/pro-life-leaders-call-on-fda-to-restore-abortion-drug-safeguards-d8f96c48f0333a28 2026-09-24T13:07:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-27-september-2026-c943810d2c68d2ca 2026-09-24T13:05:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-2026-to-2027-46b78a2386536090 2026-09-24T13:00:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-reports-2026-to-2027-season-32f74fa23fd23c69 2026-09-24T13:00:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/syndromic-surveillance-weekly-summaries-for-2026-45747e3878253def 2026-09-24T13:00:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/remote-health-advice-weekly-bulletins-for-2026-0b8fbceac342c05c 2026-09-24T13:00:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-ambulance-syndromic-surveillance-weekly-bulletins-2026-6dee157afd1fba75 2026-09-24T13:00:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/gp-out-of-hours-syndromic-surveillance-weekly-bulletins-for-2026-f212a5a75078c06e 2026-09-24T13:00:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/gp-in-hours-weekly-bulletins-for-2026-dfebf391f225843d 2026-09-24T13:00:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/emergency-department-weekly-bulletins-for-2026-08abcdde2881ef86 2026-09-24T13:00:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-you-need-new-experts-for-ai-validation-canva-01eb9bca8a13d35c 2026-09-24T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/acrp-fellow-advocates-for-workforce-support-recognition-of-the-human-element-at-adb76937931c263c 2026-09-24T12:59:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/supply-chain-signal-how-policy-pressures-are-converging-on-pharma-657d9fba122364cb 2026-09-24T12:59:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/gmp-inspections-timelines-a-critical-regulatory-challenge-for-russian-pharmaceut-e7dc698ef5110745 2026-09-24T12:53:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-upgrades-vitruvias-thyroid-drug-recall-to-highest-risk-level-628ccd913b0388b6 2026-09-24T12:51:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-equity-strategies-reports-and-tools-c0ffe1b40e5cb25d 2026-09-24T12:43:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/bionation-2026-makes-the-case-for-canadian-biotech-as-a-national-priority-ad639bc356d65e3d 2026-09-24T12:32:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/bionation-2026-makes-the-case-for-canadian-biotech-as-a-national-priority-associ-a2e87b82d11840dd 2026-09-24T12:32:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/bionation-2026-makes-the-case-for-canadian-biotech-as-a-national-priority-b9989c6df729a5ef 2026-09-24T12:32:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/complete-routine-immunisation-schedule-f183272f6e9e9379 2026-09-24T12:27:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/merck-sees-pivotal-victory-for-3b-eye-disease-prospect-c531284e9416942c 2026-09-24T12:15:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/imunon-makes-the-frontline-case-for-phase-3-imnn-001-study-14-7-month-os-signal-868d8772ba1a6b61 2026-09-24T12:11:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-first-patient-has-received-a-germ-fighting-gel-being-tested-for-infected-dia-5fb89581d66b5d03 2026-09-24T12:02:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/likoralltm-patient-lift-systems-d7a7892377661e3e 2026-09-24T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/interstimtm-systems-8f983b571970ef4c 2026-09-24T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/daewoong-pharmaceutical-presents-baseline-characteristics-of-104-patients-in-glo-8ddd06580f20c1fe 2026-09-24T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-a-us-senator-wants-a-biotech-leader-in-the-white-house-who-has-the-president-b6e7dabb5e589933 2026-09-24T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/atyr-pharma-atyr-gains-5-after-securing-fda-protocol-approval-for-phase-3-sarcoi-16bd40c5d8cb33ae 2026-09-24T11:50:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/moderna-begins-phase-1-clinical-trial-of-ebola-vaccine-against-strain-behind-drc-0f15edae8af6e558 2026-09-24T11:42:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-protection-report-volume-20-2026-f9e0b8a49f9df3c3 2026-09-24T11:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/prac-september-2026-veiligheidsonderzoek-naar-injecteerbare-ijzerhoudende-genees-d3df9ebf3c2363ce 2026-09-24T11:27:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/arwr-stock-goldman-sachs-resumes-coverage-with-74-target-as-clinical-catalysts-n-54f6027f066b31dc 2026-09-24T11:20:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/dhsc-workforce-management-information-62f452371af74327 2026-09-24T11:12:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/dhsc-workforce-management-information-august-2026-291cf16d23181a61 2026-09-24T11:11:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-second-measure-favored-the-higher-dose-the-alzheimer-s-drug-narrowly-missed-it-3c1bb4ef41c89852 2026-09-24T11:03:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/flsc-ipo-news-biotech-spac-frazier-life-sciences-acquisition-ii-files-for-a-75-m-d5eab25a2dd31e90 2026-09-24T11:01:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ono-pharmaceutical-co-ophlf-soars-13-9-is-further-upside-left-in-the-stock-0950027dcda4a100 2026-09-24T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/acadia-pharmaceuticals-announces-phase-3-enabling-topline-results-from-phase-2-r-c918ae34422e8020 2026-09-24T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/healthy-start-extension-application-guidance-84d59c59b495a9a2 2026-09-24T10:58:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/podcast-how-sandoz-plans-to-harness-its-golden-decade-68b53bc08b1c1d6f 2026-09-24T10:55:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/enveda-nabs-311m-to-progress-nature-derived-drug-pipeline-55af799b19cd9116 2026-09-24T10:52:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/ctt-pharmaceutical-adds-karen-larson-to-board-e7cff323c616d17f 2026-09-24T10:49:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/merck-s-remigromig-a-tri-specific-agonist-of-the-wingless-related-integration-si-564f990f527f019d 2026-09-24T10:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/lilly-s-fda-approved-weekly-insulin-could-mean-over-300-fewer-shots-a-year-than-a8e09cc6f5e4003a 2026-09-24T10:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/schorr-family-foundation-scholarships-help-two-pharmacy-students-c82a687b573f5292 2026-09-24T10:40:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/gohub-ventures-invests-in-swiss-biotech-startup-prevision-medicine-5b7fe1d6af0950f2 2026-09-24T10:36:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-gilead-can-t-stop-talking-about-its-ambitions-in-immunology-4e9a973d5ffa33b5 2026-09-24T10:34:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/working-for-dhsc-7fde6c0568507ce7 2026-09-24T10:31:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/krystal-biotech-stock-initiated-at-buy-by-goldman-sachs-06ed5dbd214c1bc0 2026-09-24T10:26:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-actually-went-wrong-when-a-phase-3-trial-fails-q-a-with-dr-remo-moomiaie-qa-c88ca5967f76fd20 2026-09-24T10:06:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/medicinova-announces-completion-of-last-patient-last-visit-in-the-double-blind-p-cfde8abb806f2672 2026-09-24T10:06:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-is-excelling-in-health-tech-that-s-good-news-for-the-world-30d79eb43ed47a25 2026-09-24T10:05:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/0a2b89983de35c79 2026-09-24T10:02:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-and-atyr-align-on-a-planned-lung-disease-drug-trial-for-up-to-about-372-pati-f7ff287b591c8a1e 2026-09-24T10:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/2026-909-27-2026-c0fc667f86e8537c 2026-09-24T09:56:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/caliway-reports-phase-ii-success-for-dercum-s-disease-therapy-d74330c3d4bd909c 2026-09-24T09:49:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/anti-vax-ally-of-rfk-jr-faces-senate-showdown-in-bid-to-run-fda-c94a6418d0603cf5 2026-09-24T09:33:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-visual-guide-to-vaccines-9bd59f2f55e933f2 2026-09-24T09:26:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-stocks-at-52-week-highs-tkno-mrna-atrc-ilmn-db25e51232f70ef0 2026-09-24T09:26:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/basecamp-research-secures-140m-for-ai-driven-therapies-1fb496172a1d55e7 2026-09-24T09:15:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/saudi-arabia-s-1-3-billion-biotech-push-following-riyadh-summit-1a760444b9610383 2026-09-24T09:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cspc-pharmaceutical-initiates-phase-iii-trial-of-hb1801-for-advanced-breast-canc-722961134acadef9 2026-09-24T09:04:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/abortion-pills-vaccines-and-food-safety-f-d-a-nominee-heidi-overton-faces-senate-8657d6ea819eb9f9 2026-09-24T09:02:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/japan-s-kobayashi-pharmaceutical-considering-going-private-under-japan-uk-invest-b7d7019e91da6c88 2026-09-24T09:01:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/environmental-monitoring-following-the-grenfell-tower-fire-85d5cc3f2b36adbc 2026-09-24T09:01:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-advisory-panel-endorses-grail-blood-test-for-cancer-saying-benefits-outweigh-839e5eff0a011929 2026-09-24T09:00:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-phd-to-biotech-series-clarifying-your-direction-before-you-leave-academia-32528df980be6fab 2026-09-24T08:58:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/daewoong-pharmaceutical-presents-baseline-characteristics-of-104-patients-in-glo-9e2412cd0063c035 2026-09-24T08:44:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pre-release-access-lists-cover-programme-quarterly-data-428cef6b96303d41 2026-09-24T08:30:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/pseudomonas-aeruginosa-bacteraemia-annual-data-1d797b39720d627d 2026-09-24T08:30:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/mssa-bacteraemia-annual-data-f528c463d0bdaf78 2026-09-24T08:30:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/klebsiella-species-bacteraemia-annual-data-503a503e52f5c85b 2026-09-24T08:30:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/clostridioides-difficile-c-difficile-infection-cdi-annual-data-8aca3e044b7619f2 2026-09-24T08:30:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/escherichia-coli-bacteraemia-annual-data-3f475f96b5a9b5cb 2026-09-24T08:30:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/survey-of-adult-carers-in-england-d418d708ba824a58 2026-09-24T08:30:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-surveillance-reports-2026-to-2027-season-1cc078fa257f8153 2026-09-24T08:30:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/group-a-streptococcal-infections-seasonal-activity-in-england-2025-to-2026-ce123cc7682acde2 2026-09-24T08:30:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/salmonella-statistical-releases-5659a2d745797007 2026-09-24T08:30:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/gastrointestinal-infections-and-outbreak-statistics-for-england-05961f6c3dda1ec2 2026-09-24T08:30:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/childhood-vaccine-coverage-provisional-monthly-data-england-2026-29f210faf64d1d4d 2026-09-24T08:30:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/staphylococcus-aureus-guidance-data-and-analysis-a8912dd7bdb60a2d 2026-09-24T08:30:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/pertussis-guidance-data-and-analysis-03c0c3d9c5f593d2 2026-09-24T08:30:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/rubella-confirmed-cases-and-notifications-926536a7ab5f7350 2026-09-24T08:30:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/pertussis-laboratory-confirmed-cases-reported-in-england-2026-db4e82e10f96250a 2026-09-24T08:30:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-and-mssa-bacteraemia-and-c-difficile-infections-annual-epidem-f5bcd757f0f31131 2026-09-24T08:30:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/cover-of-vaccination-evaluated-rapidly-cover-programme-2026-to-2027-quarterly-da-c123be05410e88f7 2026-09-24T08:30:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/cover-of-vaccination-evaluated-rapidly-cover-programme-2025-to-2026-quarterly-da-ec5c68eb5b9089f9 2026-09-24T08:30:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/mumps-confirmed-cases-and-notifications-c7fa17868bb576d7 2026-09-24T08:30:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/cover-of-vaccination-evaluated-rapidly-cover-programme-statistics-ba0b6fc132b9bc62 2026-09-24T08:30:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/healthcare-associated-infections-hcai-statistics-b7d400e2cae94ffc 2026-09-24T08:30:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/ukhsa-priorities-in-2026-to-2027-1952003048c98805 2026-09-24T08:30:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/ukhsa-annual-remit-letters-951394235efaad03 2026-09-24T08:30:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/healthcare-associated-infections-hcai-qmi-report-3d3a05bef1af6387 2026-09-24T08:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/survey-of-adult-carers-in-england-2025-to-2026-report-dd94c8c57d1015b9 2026-09-24T08:30:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-and-mssa-bacteraemia-and-c-difficile-infections-annual-epidem-0349e3e77f352fa2 2026-09-24T08:30:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/mrsa-bacteraemia-annual-data-41045b47b36919ad 2026-09-24T08:30:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-and-mssa-bacteraemia-and-c-difficile-infections-annual-epidem-15eaf59b1e073a25 2026-09-24T08:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/zawya-jordan-innovation-to-boost-pharmaceutical-industry-expansion-competitivene-176d20ac670397c0 2026-09-24T08:06:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/bristol-myers-squibb-announces-265-additional-job-cuts-9a849e8b43466d86 2026-09-24T07:56:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/five-reputable-food-safety-pharmaceutical-analysis-testing-comp-8d1fad0593c07239 2026-09-24T07:46:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/sweden-sees-rise-in-reported-adverse-reactions-to-semaglutide-c726e3240e922ecd 2026-09-24T07:32:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/medienmitteilung-klinische-forschung-unter-druck-die-schweiz-verliert-den-anschl-f10a4dd63d4b7ad6 2026-09-24T07:12:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/astellas-starts-phase-3-trial-of-setidegrasib-vs-docetaxel-in-kras-g12d-lung-can-04158db7875be88d 2026-09-24T06:43:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/aurion-biotech-completes-enrolment-in-pivotal-phase-3-astra-trial-of-aurn001-054fc721ae97f0f7 2026-09-24T06:41:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/2026-1816dbb998f2b4ff 2026-09-24T06:39:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/lilly-puts-up-100m-plus-billions-on-the-backend-to-form-5-target-deal-with-china-6c61ef54a1649f1c 2026-09-24T06:39:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/8ebee4139de8b40a 2026-09-24T06:36:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/europe-s-opportunity-to-capture-the-value-in-china-biotech-mcdermott-will-schult-085f959c32a8b182 2026-09-24T06:36:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/iii-imagination-a496c4076e536916 2026-09-24T06:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/roche-s-announcement-regarding-sefaxersen-announcement-of-interim-analysis-resul-2b62b1533500f4e4 2026-09-24T06:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/senators-to-question-fda-nominee-about-her-views-on-abortion-pill-and-vaccines-7927482d11e62167 2026-09-24T06:10:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-mrna-player-arcturus-buys-belgian-biotech-myneo-d16ed4fa7c90683b 2026-09-24T05:46:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-scientific-excellence-to-industrial-implementation-7d269cad5f6bcd35 2026-09-24T05:31:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/scancell-completes-up-to-us-25-million-in-debt-financing-providing-optionality-a-bf9b9582e6d48052 2026-09-24T05:02:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-open-innovation-how-to-make-pharma-biotech-collab-work-at-scale-56c6678157e4dce8 2026-09-24T05:00:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/small-biotech-can-outsource-the-work-but-not-the-thinking-62440c8a0f80ffa8 2026-09-24T04:48:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/sls-ibrx-eye-green-month-as-biotech-etf-gains-steam-analyst-sees-continued-oppor-6a1aa66cf3396998 2026-09-24T04:30:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/oncolytics-biotech-nasdaq-oncy-trading-down-5-2-time-to-sell-0ef78dc82ada9778 2026-09-24T04:23:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-suspends-licence-of-big-basket-outlet-2-others-in-pune-983a0d3619458216 2026-09-24T04:01:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/forge-nano-and-nanexa-enter-joint-development-agreement-to-advance-manufacturing-ba5c9042fb0dd3d3 2026-09-24T03:43:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/relay-therapeutics-stock-in-focus-as-phase-3-trial-begins-ae162c061bbbe4de 2026-09-24T03:40:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-gravity-what-happens-when-biotech-leaves-earth-f07a29aa63bed1c2 2026-09-24T03:19:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-fine-chemicals-market-research-by-the-business-research-company-h-d995cc154853c988 2026-09-24T02:15:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/denmark-s-novo-nordisk-drives-pharmaceutical-growth-amid-economi-614c7030a4d75324 2026-09-24T01:30:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/veraxa-biotech-nasdaq-vrxa-appoints-raju-willener-as-chief-financial-officer-f28b533ec19df462 2026-09-24T01:29:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-limited-teva-stock-price-news-quote-and-history-fc990b185865c912 2026-09-24T01:13:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/otsuka-presents-new-phase-3b-results-for-simtriyo-centanafadine-highlighting-con-1a29f0f899bb75bd 2026-09-24T01:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/south-korea-s-cellid-sells-control-to-huniverse-global-bluemtec-goes-to-kolmar-g-3f9c640f1bbe8a4b 2026-09-24T00:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/state-street-spdr-s-p-biotech-etf-xbi-stock-price-news-quote-and-history-c439df664c2384a2 2026-09-24T00:48:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/hlb-wins-fda-nod-for-fgfr2-cholangiocarcinoma-drug-targets-q4-us-launch-chosunbi-1f8b2d48bd4073d8 2026-09-24T00:36:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/kringle-pharma-seeks-u-s-phase-3-trial-for-spinal-cord-injury-drug-14edbc70749803b0 2026-09-24T00:33:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/gsk-filed-form-6-k-ad72045ab683f604 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-d3f013665ddaf50f 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-443ea740c7e69f2e 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-38a38cc651371f60 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-f5553c80e908f2c8 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-06139b71cc0c153b 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-233ae5c1e061737f 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-172118f52588403e 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-713ee91cfbca7345 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-6444b7eb9bd533c5 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-b13e77112b2bd209 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-9a2ffc4b39550df0 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-5d34321111493c16 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-9a0cdccf6bfe7223 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/home-page-17a9ae42e7bab440 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-center-program-performance-period-extensions-0f0cd04cdb1c8a07 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-institute-on-deafness-and-other-communication-disorders-notice-of-close-ba042779be6415ec 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/announcement-of-the-intent-to-award-a-single-source-cooperative-agreement-to-int-196740f909292d40 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/improving-patient-access-to-deceased-donor-islet-cells-and-cell-products-request-7c8bf0c1fd2bd478 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bulk-manufacturer-of-controlled-substances-application-cayman-chemical-company-83551c67b2dddf3e 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bulk-manufacturer-of-controlled-substances-application-eli-elsohly-laboratories-7b874ac6769188b4 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/importer-of-controlled-substances-application-fisher-clinical-services-inc-i-22f4ec8f816e8d51 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/importer-of-controlled-substances-application-cambridge-isotope-laboratories-inc-339a6737685ac403 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bulk-manufacturer-of-controlled-substances-application-cambridge-isotope-laborat-5e9cedccc508e97d 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/request-for-information-medicare-part-d-reasonable-and-relevant-pharmacy-contrac-a32ed7dcd8d4274e 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-evaluation-of-levels-of-vitamin-d-and-cementum-thickness-and-clinica-56654c30b5b58af4 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-risks-associated-with-traumatic-exposures-among-flood-disaster-victims-in-5b55d48739ec2191 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/precision-medicine-in-diffuse-large-b-cell-lymphoma-integrating-molecular-biomar-e12408836930ea28 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/efficacy-of-transcatheter-arterial-embolization-plus-targeted-chemotherapy-for-a-dfcd1446063adacc 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tubulocystic-renal-cell-carcinoma-with-aggressive-behavior-insights-from-molecul-d6bf7b15a82a28e4 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/correlations-of-the-expression-of-akap95-cx43-cpsf5-6-scffbxl2-and-scffbxo31-in-457d4f522a00c9ed 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/peer-review-report-for-effects-of-transcutaneous-electrical-stimulation-on-perip-083d3f36c265066e 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/snake-antivenom-therapy-for-improving-outcome-in-russell-s-viper-envenomation-sa-8b0d24c073b55439 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/measuring-nca-outcomes-665cec7eddea2887 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/topical-and-systemic-nca-interventions-b325eeec46041d2f 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/disrupting-hierarchies-of-knowledge-and-strengthening-collective-wisdom-e4b32b559b1fa8d2 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/physical-activity-and-exercise-in-pediatric-oncology-conceptual-distinctions-and-0aa355a994cf5c81 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effectiveness-of-vestibular-electrical-stimulation-combined-with-vestibular-reha-eaef322f5700f043 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-radiological-outcomes-of-percutaneous-k-wire-fixation-versus-open-r-083f8f81779d12e2 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-utility-of-neck-imaging-reporting-and-data-system-in-post-treatment-sur-4b6e85ce06f08615 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/41-metabolic-dysregulation-and-immune-activation-in-vitiligo-unveiling-the-mitoc-a1301e9a89728dbf 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-characteristics-associated-factors-and-mortality-related-factors-of-pne-f48946eb2b5492dd 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/epidemiology-genetics-clinical-characteristics-and-dietary-risk-factors-of-famil-51e317c6f6c3535b 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/areszt-elektroniczny-a-ograniczenie-skali-stosowania-tymczasowego-aresztowania-e7128e91325fe374 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/critical-care-ultrasound-guided-targeted-volume-management-as-precision-medicine-e319763ba39afdc9 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/antibiotic-prophylaxis-of-infective-endocarditis-in-dentistry-an-update-on-the-e-9e0a810bc5198dd3 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/perioperative-outcomes-of-multivessel-minimally-invasive-coronary-revascularizat-9a13b25dc7aea994 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/managing-choledocholithiasis-in-rare-congenital-hepatobiliary-anomalies-a-report-acb1ff9b5c98f97c 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/handgrip-strength-relative-to-estimated-skeletal-muscle-mass-and-threshold-defin-7cbe553532899c08 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-impact-of-changes-to-the-payment-restrictions-of-the-national-reimbursement-2a6860a059aca4d9 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/distinct-molecular-landscape-and-clinical-subtype-of-hpv-positive-esophageal-squ-f21f3f790fac31eb 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/psoriasis-and-bullous-pemphigoid-an-updated-review-of-clinical-association-targe-419f7c5d8d17be8a 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/role-of-the-gut-microbiome-in-natural-and-synthetic-drug-efficacy-and-safety-a-n-a0533936020f92e9 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrated-electrophysiological-and-payload-release-assessment-of-neuronal-respo-f1dfbb664f726b56 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pediatric-hearing-loss-in-the-universal-newborn-hearing-screening-era-etiologies-f07e99478d594e3d 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/incidence-burden-and-associated-factors-of-severe-potential-drug-drug-interactio-000263b0d1b1ca97 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-efficacy-and-safety-evaluation-of-dexmedetomidine-hydrochloride-nasal-s-cffd6c1dca84e355 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/strengthening-the-interpretation-of-longitudinal-eqa-data-through-the-sporadic-i-b9fb7e0dd74e7ef1 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-efficacy-and-pregnancy-outcomes-of-doxycycline-plus-medroxyprogesterone-67f55084828f7378 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/diagnostic-performance-of-digital-and-clinical-approaches-for-detection-of-podoc-e46d474d49be2259 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/periodic-fever-aphthous-stomatitis-pharyngitis-adenitis-clinical-manifestations-300bd22349cb7d3a 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-contribution-of-mngs-in-the-diagnosis-and-management-of-imported-falcip-f7d332a21c9659e8 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-trials-on-3d-bioprinted-scaffolds-for-lower-extremity-vascular-diabetic-c3b698dce392e375 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/surface-marker-defined-functional-subpopulations-of-mesenchymal-stromal-cells-me-7c9f34b112f5444f 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nonresponse-to-intravitreal-anti-vegf-therapy-for-retinopathy-of-prematurity-cli-2ab291d4acdae5d7 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/investigation-of-potential-drug-drug-interactions-due-to-linezolid-use-in-anesth-9387ce60364a4bc5 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/therapeutic-effects-of-lentinan-in-gastrointestinal-inflammation-and-carcinogene-6b0c8444a3b58127 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/impact-of-an-oral-amino-acid-containing-formulation-on-clinical-and-functional-o-1593243086615193 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/dna-methylation-biomarkers-from-precancerous-lesions-to-adenocarcinoma-in-the-st-a86ae7786dc25552 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/vespula-spp-venom-immunotherapy-basophil-excitability-and-fc-ri-fc-riib-expressi-9fb9de0999d796fe 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-pea-protein-enriched-snacks-and-vitamin-d-supplementation-on-the-progr-90b2d33384ecf18c 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/emotional-disclosure-for-alleviating-depression-anxiety-and-stress-in-women-afte-386ec9a3a7de9df0 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/local-infiltration-versus-intramuscular-esketamine-for-procedural-pain-and-posto-2318a0d193c092bf 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comprehensive-evaluation-of-plasma-proteomics-platforms-toward-practical-applica-e7db85d32b44d1b4 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-characteristics-and-outcomes-of-hypertrophic-cardiomyopathy-associated-e0f6f3c7bfda81eb 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/multi-criteria-decision-analysis-of-dendrimer-applications-in-drug-delivery-syst-041e66390a001be0 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/heterogeneity-of-breast-and-nodal-response-to-neoadjuvant-pembrolizumab-based-ch-f56993f250266eb1 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/triage-administration-of-ondansetron-for-gastroenteritis-in-children-8cc45fd4d1f1be8d 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/letter-to-the-editor-an-acceptance-based-healthy-lifestyle-programme-for-communi-9e8b88965342ff19 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-molecular-metabolic-and-clinical-aspects-of-human-selenoproteins-a-narrative-9fed693ac9ae7fc1 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/establishing-the-value-of-call-handling-metrics-in-a-united-kingdom-poisons-info-96d501ba8dbd4d6c 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/surgical-telementoring-platforms-for-clinical-care-and-training-a-systematic-rev-417edb1bfd1a54b1 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/psychosocial-and-clinical-factors-associated-with-diabetes-self-management-in-ty-ff48bf860447a18b 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sustained-intravitreal-delivery-of-triamcinolone-acetonide-via-in-situ-forming-l-5c18ed713309c5c3 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/targeting-exosome-conjugated-with-cardiac-homing-peptide-alleviates-myocardial-i-da0e401a6a4a33e0 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-repeal-of-the-ntap-alternative-pathway-will-impact-u-s-clinical-ai-innovatio-73bf9e1dbd1e638f 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-technical-performance-to-clinical-readiness-a-phase-based-framework-for-evi-2073a706a466abd2 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/new-approach-methodologies-drug-screening-platform-to-identify-antifibrotic-comp-bc05f6f071d85d54 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/waterless-mof-des-eutectogels-with-adaptive-viscoelasticity-for-dual-hydrophilic-d2680ba1651e875d 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/analyzing-and-redesigning-deployment-pathways-for-internally-developed-artificia-af509b768608b3f5 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/response-to-correspondence-pharmacogenomics-and-digital-adherence-tools-a-commen-ec0f525822d42de2 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/supramolecular-salicylic-acid-chemical-peeling-combined-with-supramolecular-acti-b0f0423ae96908dd 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-effects-of-coenzyme-q10-supplementation-on-exercise-induced-oxidative-stress-93afc53a8c0ba492 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrating-q-rung-picture-fuzzy-hypersoft-sets-with-aczel-alsina-operators-for-5f96258fcdd82d41 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/staged-radiotherapy-for-symptomatic-unresectable-giant-hepatic-hemangiomas-with-748970dca67acc07 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/establishing-antidiabetic-potential-of-navayasa-churnam-phyto-metabolomics-syste-c0392b5a87139d5d 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/human-neuroangiostrongyliasis-caused-by-angiostrongylus-cantonensis-in-northern-e5359583bc4dbfd4 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-predictors-of-at-risk-mental-states-in-general-adolescent-population-a-ca29d77470e7ce30 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/subsequent-depression-in-patients-with-lip-and-head-and-neck-cancer-a-population-d779f0bbe3d24fa6 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/correction-to-age-specific-patterns-of-lymph-node-involvement-in-elderly-patient-0db7585dd0d8bb83 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gnal-associated-dystonia-clinical-spectrum-genetic-features-and-genotype-phenoty-89faae5b45271657 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/letter-to-the-editor-on-clinical-and-logistical-determinants-of-operative-timing-ec647449118c39c7 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/correction-to-an-excitation-customized-ict-type-turn-on-probe-for-visualization-e2c8a53da25d0c12 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/updated-estimates-of-agreement-between-dispensed-medications-and-forensic-toxico-518bf5af11781f67 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-management-and-outcomes-of-neonatal-rhinitis-nasal-obstruction-a-scopin-8975fc8cab937599 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/treatment-duration-and-clinical-response-patterns-of-laryngopharyngeal-reflux-di-94bf8b18875eb65b 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/scp-expression-of-concern-scp-randomized-controlled-trial-comparing-ondansetron-aa25d492a6d17cf4 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/virtual-reality-for-anxiety-and-pain-management-in-lower-limb-orthopedic-surgery-8580b8bb44e53af4 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/laparoscopic-splenectomy-for-a-completely-infarcted-wandering-spleen-after-prolo-e4accf4b5864dd95 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/scp-igg4-scp-to-scp-igg-scp-ratio-and-orbital-involvement-predict-clinical-respo-4f3b8f715383dd93 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07839767-treatment-selection-by-3d-bioprinting-liver-model-to-prevent-liver-c-73ca2158e5a1d5d9 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07839676-a-prospective-study-of-concurrent-hyperthermia-chemotherapy-and-radi-bcfddab6e768c51e 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07839429-effect-of-mhealth-intervention-on-oral-health-related-quality-of-lif-03ae595228cb3fbf 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07839390-determination-of-the-best-therapeutic-strategy-interventional-with-b-7c88aba6b78c8f50 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07839143-a-prospective-multicenter-randomized-parallel-controlled-superiority-835dc5046489ff3d 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07838792-theory-guided-socratic-ai-scaffolding-for-clinical-reasoning-in-nurs-46fa6ed30d0194ee 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07838519-personalizing-veterans-lung-cancer-screening-and-diagnosis-b91b2ffab0a2d9e2 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07838415-multimodalomics-based-construction-of-spatiotemporal-characteristics-5670e10fd7be4982 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07838389-evaluation-of-donor-derived-b-cell-infusions-in-patients-with-amyotr-6d8c441a36cb372a 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07837960-exploration-of-diagnosis-etiology-and-prognosis-prediction-of-cracke-9986ebb45114f2e6 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07837921-post-market-clinical-follow-up-to-assess-the-portable-nitric-oxide-g-9f2721f8484594f7 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07835100-probiotics-for-sustained-health-0bd133d29e3e07c1 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07829224-effects-of-green-tea-mouthwash-on-halitosis-periodontal-health-and-s-93034438aa1638bb 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07804719-possible-sarcopenia-sarcopenia-and-functional-status-in-patients-wit-c03b1338aa2a5c39 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07792148-adapting-the-esteem-intervention-to-improve-mental-health-and-prep-u-99a67792a1ad2864 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07758985-safety-tolerability-pharmacokinetics-and-mosquitocidal-activity-of-l-dae09b2c2f32117f 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07748585-effect-of-titanium-prepared-platelet-rich-fibrin-and-low-level-laser-9905f16d40902696 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07743151-a-clinical-trial-of-mk-1406-in-healthy-participants-mk-1406-008-e8eaa30f431ccd48 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07718724-impact-of-gdmt-in-uncontrolled-asthma-patients-receiving-mhd-inhaled-e94a608d12789aa8 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07715903-hepatic-artery-infusion-of-carfilzomib-in-participants-with-liver-me-c34d97c9f5173517 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07659938-frontal-gamma-coherence-neurofeedback-for-patients-with-schizophreni-81705dac9dc518ed 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07559929-a-study-of-dxc006-with-immune-checkpoint-inhibitors-or-platinum-for-1f8a9402a0540504 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07468695-feasibility-study-comparing-use-of-one-or-two-probes-for-thermal-abl-2ba43ec1db3fe996 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07262983-evaluating-the-safety-and-tolerability-of-baricitinib-in-patients-wi-834c49c5b61fdd2a 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07176390-a-clinical-study-of-tulisokibart-mk-7240-to-treat-rheumatoid-arthrit-dbaf95e2920ec211 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06911008-mti-301-for-the-treatment-of-metastatic-or-unresectable-and-refracto-17b496678483e328 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06891781-investigating-adaptive-deep-brain-stimulation-in-parkinson-s-disease-d76735e44e3d5b8f 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06799286-a-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-pre-9ba7328ab5818a5a 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06714591-evaluate-the-safety-tolerability-pharmacokinetic-profile-efficacy-of-d8a0669bb7483b51 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06664814-an-open-label-phase-2-study-of-n-acetyl-d-mannosamine-mannac-in-subj-9877c6064cd79368 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06649812-testing-the-effectiveness-of-a-combination-targeted-therapy-vipor-fo-e14d4ad232d4bf26 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06605404-pan-tumor-mrd-study-7899044323ff4d92 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06559891-thrive-therapeutic-intravascular-ultrasound-tivustm-renal-denervatio-7e5a898f7c07c279 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06496178-a-phase-3-study-to-evaluate-petosemtamab-compared-with-investigator-f242ef17ac83768d 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06299319-feasibility-clinical-effects-and-safety-of-psilocybin-assisted-psych-50ae9f844280d2a4 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06270316-safety-pk-pd-and-exploratory-efficacy-study-of-amt-191-in-classic-fa-6a684f5b33f662b4 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06177691-hybrid-closed-loop-therapy-and-verapamil-for-beta-cell-preservation-87ea3be44bd5d67e 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06172296-dinutuximab-with-chemotherapy-surgery-and-stem-cell-transplantation-1b596c853203ca11 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06131372-a-research-study-to-see-if-kidney-damage-in-people-with-chronic-kidn-578e512f0482adb1 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06081010-fchv-htn-implementation-trial-in-nepal-194420f26967ba3c 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06000748-neph-rosis-nephrology-in-cirrhosis-pilot-trial-a-trial-to-treat-acut-c0cc788849a22b44 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05946629-selution-4-de-novo-small-vessel-ide-trial-d7f4a6e4c6a16aed 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05773274-comparing-retreatment-of-177lu-dotatate-prrt-versus-the-usual-treatm-bea045017e16a062 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05757687-evaluation-of-the-safety-tolerability-and-efficacy-of-the-omega-syst-03e122565f0adf8a 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05669222-the-favor-v-ami-trial-1037b870a700016f 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05621291-a-multicenter-study-to-evaluate-next-generation-sequencing-ngs-testi-b35317055f480c6e 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05215340-study-of-dato-dxd-plus-pembrolizumab-vs-pembrolizumab-alone-in-the-f-be0102e5a66bd1fd 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04339270-chronic-airway-disease-mucus-rheology-and-exacerbations-9e70b71c37f34208 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct00924196-natural-history-study-of-patients-with-neurofibromatosis-type-i-e33d6a0d6b3f308c 2026-09-24T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cellid-bluemtec-rally-on-change-of-control-deals-inventera-gains-279029e5eedb31ac 2026-09-23T23:54:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/cellid-bluemtec-rally-on-change-of-control-deals-inventera-gains-k-bio-pulse-ddd3aa5d40251ec1 2026-09-23T23:37:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/astellas-doses-first-patient-in-phase-3-study-of-setidegrasib-in-previously-trea-935385bd343d9a9d 2026-09-23T23:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/west-pharmaceutical-services-i-wst-stock-forecasts-398c8f9315345cfa 2026-09-23T23:22:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/moleculin-biotech-inc-mbrx-stock-price-news-quote-history-d7c26e9dfccad274 2026-09-23T23:05:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/can-this-biotech-innovation-halt-the-destructive-march-of-a-cereal-killer-3d54d3360d238eac 2026-09-23T23:00:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/is-teva-pharmaceutical-industries-teva-undervalued-following-new-phase-3-schizop-d925da119001e5c1 2026-09-23T22:33:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/phase-3-data-could-make-roche-drug-a-contender-to-treat-rare-kidney-disease-373f4e947a97b2b4 2026-09-23T22:14:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/stealth-tactic-makes-chemotherapy-smarter-f5c2518014bb4ff0 2026-09-23T21:27:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-to-report-third-quarter-2026-financial-result-36a5a6e45481d27b 2026-09-23T20:50:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/federal-court-enters-consent-decree-against-gold-star-distribution-inc-following-512ca83e8b0ada73 2026-09-23T20:40:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-lirafugratinib-for-advanced-fgfr2-cholangiocarcinoma-577ff202acb6b4ef 2026-09-23T20:17:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-share-grant-led-to-a-tax-related-sale-legend-biotech-legn-cfo-received-19-676-63772b78d4a2cd05 2026-09-23T20:16:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-stocks-widely-dive-here-are-the-hardest-hit-6f022ab383ea840c 2026-09-23T20:12:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/zymeworks-completes-acquisition-of-theravance-biopharma-e7abdc6fed51279d 2026-09-23T20:02:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/statement-on-fda-s-warning-letter-to-empower-pharmacy-for-producing-drug-product-808db959903e7461 2026-09-23T19:48:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/state-street-spdr-s-p-biotech-etf-xbi-stock-price-news-quote-history-d4dae5114aa6fc80 2026-09-23T19:31:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-commits-to-lowering-select-medicaid-drug-costs-in-us-deal-989bbca238192ff9 2026-09-23T19:17:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-update-for-winrevair-based-on-phase-3-hyperion-trial-data-1de1c592cb071425 2026-09-23T18:29:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-food-safety-and-drugs-administration-seeks-price-cap-on-essential-medi-5cbb84318e38421d 2026-09-23T18:17:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-health-active-responsive-materials-development-stability-safety-a-bf4ed37261c96c41 2026-09-23T18:06:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-from-molecules-to-brain-health-a-framework-for-european-excellenc-4c2ddfe2c9c5c79d 2026-09-23T18:05:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-colour-and-patterns-as-fundamental-and-applied-training-playgroun-9a1ed4c01f204816 2026-09-23T18:05:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/ai-drug-discovery-s-new-frontier-competing-for-data-assets-virtual-cells-and-org-2cc9bf94b788c23e 2026-09-23T18:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-european-clinical-research-infrastructure-network-2030-122633066644981b 2026-09-23T18:04:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-pediatric-clinical-research-infrastructure-service-model-7ce354e83b800a93 2026-09-23T18:04:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/drugmaker-astellas-looks-to-sell-u-s-headquarters-in-northbrook-a5e6a86dc138ed43 2026-09-23T18:04:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-seizure-cluster-relief-through-smart-therapeutic-management-65b7869edefb7046 2026-09-23T18:02:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/can-this-biotech-innovation-halt-the-destructive-march-of-a-cereal-killer-21dcbc1414047dd9 2026-09-23T18:01:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-cardio-oncology-multidisciplinary-patient-assistance-solution-0fae8f4b4eab75ca 2026-09-23T18:00:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/is-pharma-s-operating-model-being-rewritten-1bd526557033e831 2026-09-23T17:56:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/immunovant-stock-slides-after-biotech-scraps-autoimmune-drug-program-a060f5478bcaac74 2026-09-23T17:44:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/mike-doustdar-open-to-direct-listing-for-novo-shares-pharmexec-fdbd724d0a2d9419 2026-09-23T17:29:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/new-orleans-biotech-informuta-wins-1-25m-nsf-grant-b1d18ceb24c761cb 2026-09-23T17:15:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/viking-therapeutics-strong-buy-on-injectable-vk2735-maintenance-data-and-treatme-2e88ffec779c1167 2026-09-23T17:09:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/september-highlights-a-defined-path-from-enrollment-to-data-to-regulatory-submis-546ba70def50c57b 2026-09-23T16:54:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/roche-ionis-rna-drug-scores-in-kidney-disease-study-4f1c7b194b826b87 2026-09-23T16:26:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/africa-needs-more-medicines-can-its-pharmaceutical-industry-keep-up-9a8de728ab5d07fe 2026-09-23T16:20:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharma-ai-2026-fall-update-preview-agentic-ai-takes-the-wheel-of-pharmaceutical-eec65fbc2b19e4c5 2026-09-23T16:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-issues-new-guidelines-on-fentanyl-related-crimes-clarifies-sentencing-stan-d40ab24fc3aaf703 2026-09-23T15:51:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmap-2027-addresses-the-future-of-pharmaceutical-manufacturing-and-packaging-a24f87902f85969a 2026-09-23T15:47:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/amgen-s-dazodalibep-meets-primary-endpoint-in-phase-3-sjogren-s-trial-86c74bc3b8f5dcad 2026-09-23T15:46:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-packaging-materials-and-drug-compatibility-2f30272ed752ddb3 2026-09-23T15:43:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/can-immunotherapy-stop-the-clock-on-type-1-diabetes-01c89bbc9df567f0 2026-09-23T15:42:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/37-000-ai-agents-are-running-a-virtual-biotech-at-stanford-aa00bf1f361ce5fe 2026-09-23T15:41:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/eli-lilly-vs-pfizer-in-2027-one-is-a-much-better-place-to-park-your-pharmaceutic-4de0a023ca1e4643 2026-09-23T15:32:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/9-pharma-leaders-sound-alarm-bells-on-biotech-s-decline-in-europe-8cae6dd44987e769 2026-09-23T15:31:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/ubc-okanagan-boosts-biotech-growth-jobs-in-kelowna-b5445b438b22e3df 2026-09-23T15:26:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/covid-19-vaccination-vaccine-product-information-2f002a54e328b7a9 2026-09-23T15:24:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/sweden-a-powerhouse-for-early-stage-innovation-32336554ff8d853f 2026-09-23T15:19:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/jaguar-health-plunges-59-and-viking-therapeuti-db83db73d7dc3b68 2026-09-23T15:14:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/petroliferos-lobo-and-oz-studio-expand-trace-from-petroleum-into-pharmaceutical-d8b3b5494ab74d32 2026-09-23T15:06:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/new-safety-module-in-the-clinical-trials-information-system-ctis-50e683a4919aefce 2026-09-23T15:02:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/europe-s-pharma-chiefs-warn-bloc-is-losing-innovation-race-dd74789b50fb2c08 2026-09-23T14:56:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/students-fill-high-paying-biotech-jobs-7b177440d9c34a4e 2026-09-23T14:52:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/expres2ion-biotech-holding-ab-exprs2-secures-sek-19-3m-to-13-exercise-1-1-b1ec93da641bbb8d 2026-09-23T14:50:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/european-big-pharma-unites-amid-ringing-alarm-bells-of-continents-dominance-42c06e624a767769 2026-09-23T13:54:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/amgen-asset-from-27-8b-horizon-buy-scores-in-phase-3-sjogren-s-study-c6347dd93b97ff66 2026-09-23T13:52:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/bit-bio-partners-with-miriamed-to-bring-human-cardiomyocytes-to-its-drug-discove-6dfc3ef16dd20840 2026-09-23T13:47:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/enveda-reaps-311m-series-e-to-feed-ambition-to-become-a-household-name-f72260477437e222 2026-09-23T13:47:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/flagship-gets-a-pentagon-contract-fcb7bac7859a0771 2026-09-23T13:38:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/maia-biotechnology-expands-pivotal-phase-3-thio-104-non-small-cell-lung-cancer-t-410cbc55b527a9d2 2026-09-23T13:32:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/jedco-innovation-to-boost-jordan-s-pharmaceutical-industry-expansion-competitive-60088197bf5af4b5 2026-09-23T13:29:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/public-mental-health-autumn-webinar-school-based-mental-health-interventions-9698cdb22343e0dc 2026-09-23T13:28:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/q-a-why-ndc-12-readiness-has-to-happen-before-day-one-b1cd27b1952015f8 2026-09-23T13:26:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/penny-stock-vistagen-analyst-highlights-caution-after-anxiety-data-608d73e82bd1b1da 2026-09-23T13:25:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/about-30-000-new-lung-cancer-cases-occur-yearly-in-spain-and-portugal-a-trial-ha-0bd639da70000348 2026-09-23T13:17:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/concord-biotech-announces-1-1-bonus-share-issue-shareholders-to-get-one-free-sha-e452dcfda4d71e2b 2026-09-23T13:15:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/rbc-says-ai-weakness-appears-to-be-fueling-biotech-rally-f7ddd140c25173b3 2026-09-23T13:13:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/amylyx-pharmaceuticals-inc-amlx-stock-price-news-quote-and-history-881f9021c1f02419 2026-09-23T13:10:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/aurion-biotech-completes-enrollment-in-phase-3-astra-trial-of-aurn001-for-cornea-d5b3dd232e1b81b4 2026-09-23T13:09:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/enveda-raises-311-million-from-leading-ai-and-biotech-investors-to-bring-pharma-d2d89fe7cfa4c511 2026-09-23T13:08:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-chief-tukaram-mundhe-welcomes-bollywood-actors-support-for-food-7704108b6ff5afbe 2026-09-23T13:06:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/new-yorkers-prescribed-generic-drugs-could-be-entitled-to-share-of-96m-settlemen-079f2f04be6ccf19 2026-09-23T13:05:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/class-4-medicines-defect-notification-b-braun-melsungen-ag-meropenem-1000-mg-pow-c017a279be305219 2026-09-23T13:00:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/two-men-joined-forces-at-a-biotech-firm-one-is-being-hailed-for-his-work-to-cure-b32648efcb588026 2026-09-23T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/main-sequence-backs-dementia-biotech-kinoxis-in-a-9-25m-round-1e029c7e02718a39 2026-09-23T12:53:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-tukaram-mundhe-led-fda-expands-food-safety-drive-to-schools-festival-ff43b1c3c042f5f4 2026-09-23T12:52:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/anmat-alerta-sobre-solicitudes-de-datos-en-nombre-del-organismo-920bc6d837759649 2026-09-23T12:44:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/anmat-dispuso-la-cancelacion-de-certificados-de-especialidades-medicinales-que-n-878404cca01dfa0e 2026-09-23T12:37:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/cphi-milan-2026-preview-key-themes-and-emerging-trends-64ad898e4b3525ce 2026-09-23T12:33:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/dcoy-stock-whipsaws-as-traders-game-biotech-volatility-f2eafaf137ceaf88 2026-09-23T12:33:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-drug-formulation-designed-to-reach-lung-tumors-has-mexican-patent-protection-t-9a6226bbb164d9be 2026-09-23T12:29:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/6-moonshot-biotech-stocks-that-offer-big-risks-bigger-rewards-2ec5afb22e0bf892 2026-09-23T12:28:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/oppenheimer-initiates-coverage-on-teva-pharmaceutical-industries-nyse-teva-d07bac4ace81e494 2026-09-23T12:27:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/moleculin-nasdaq-mbrx-lowers-warrant-price-while-stating-it-needs-trial-funding-37feb91e0c967f74 2026-09-23T12:25:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/moleculin-biotech-secures-mexican-patent-protecting-lung-targeted-liposomal-anna-72c1ed32316517e8 2026-09-23T12:25:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/aurion-biotech-completes-enrollment-in-pivotal-astra-phase-3-study-advancing-aur-900b781ebb8e9b5b 2026-09-23T12:19:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/european-pharmaceutical-sector-faces-decline-amid-global-competition-87e90953660cdc78 2026-09-23T12:06:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/enveda-raises-311-million-from-leading-ai-and-biotech-investors-to-bring-pharma-dc35a2b891936318 2026-09-23T12:00:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/williams-cystoscopic-injection-needle-6c20102f9f238606 2026-09-23T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/omniasecuretm-mri-surescantm-2d8833077cd38fa9 2026-09-23T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/dcoy-stock-whipsaws-as-traders-target-biotech-volatility-4c2712f525e7e336 2026-09-23T11:48:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/2026-1d5604d4a504007c 2026-09-23T11:39:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-biotech-growth-trust-plc-why-biotech-s-recovery-could-still-have-further-to-310d1862d2e9b283 2026-09-23T11:27:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/viking-s-vk2735-shows-durable-weight-loss-with-less-frequent-maintenance-dosing-03f08420126a796f 2026-09-23T11:23:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/oppenheimer-initiates-collegium-pharmaceutical-stock-at-outperform-c9f41444cb0d0522 2026-09-23T11:19:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/bollywood-actors-back-tukaram-mundhe-s-food-safety-drive-fda-chief-says-grateful-d2aaf98462181b67 2026-09-23T11:02:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/americans-should-not-be-experimenting-with-peptides-that-is-the-fda-s-job-1e92ac73cc966e7d 2026-09-23T11:01:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/scientists-are-testing-an-unexpected-new-weapon-against-screwworm-7d6cd17f448fee72 2026-09-23T11:00:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/ukhsa-expands-wastewater-surveillance-to-strengthen-early-warning-system-for-dan-cebf5a4b17395e76 2026-09-23T11:00:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/aurion-biotech-completes-enrollment-in-pivotal-astra-phase-3-study-advancing-aur-b6711b307932a822 2026-09-23T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/henlius-looks-to-us-biotech-for-global-tce-rights-in-amberstone-deal-61b48e357cb64d42 2026-09-23T10:35:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/jefferies-raises-amgen-stock-price-target-on-drug-trial-success-cc7e529ee5fe6e74 2026-09-23T10:21:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/roche-proposes-former-takeda-ceo-christoph-weber-for-board-seat-eb5e783eba6901a0 2026-09-23T10:11:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/shanghai-henlius-biotech-inc-and-amberstone-biosciences-inc-enter-collaboration-fc21a4575dc1493d 2026-09-23T10:05:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/ai-biotech-startup-enveda-doubles-in-value-to-2-billion-wsj-2a17d33df3769840 2026-09-23T10:03:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/abortion-statistics-user-engagement-plan-65fe5013a86b6246 2026-09-23T10:00:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/abortion-statistics-in-england-and-wales-62845a4d19ed888c 2026-09-23T10:00:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/exclusive-ai-biotech-enveda-doubles-in-value-to-2-billion-a869218d6b806c02 2026-09-23T10:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/jimmy-kimmel-trolls-trump-s-allies-with-parody-pharmaceutical-ad-b474764485d9f9c8 2026-09-23T09:59:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/polyurethane-tubing-for-biotech-market-to-2035-biopharma-capacity-expansion-driv-2c9779b6fa8fae8d 2026-09-23T09:46:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-companies-push-trump-administration-to-protect-china-deals-40671ca1388c0776 2026-09-23T09:42:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/pune-fda-suspends-licences-of-rangla-punjab-manisha-dosa-center-over-safety-viol-27217126f6acd7c7 2026-09-23T09:40:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/nine-european-pharma-chairs-warn-of-slow-agony-as-investment-slips-1254cc631db64b03 2026-09-23T09:22:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/otsuka-and-ionis-report-positive-phase-iii-readout-for-ulefnersen-36ca2d60798ce8df 2026-09-23T09:22:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/drugmakers-biotech-vcs-show-reinvigorated-interest-in-osteoporosis-treatments-ed6a223fc4d8d0a9 2026-09-23T09:15:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/doustdar-on-plunging-share-price-reflects-level-of-confidence-in-the-company-and-73e26491eface571 2026-09-23T09:04:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/field-safety-notices-14-to-18-september-2026-e1fc284848d2c91c 2026-09-23T09:03:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/transparency-data-mhra-performance-data-d981698b76b6bbf6 2026-09-23T09:00:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/keep-britain-working-20e801e2a2496745 2026-09-23T08:58:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/ionis-pharmaceuticals-phase-3-kidney-trial-meets-proteinuria-endpoint-a1f79eed08f46dc9 2026-09-23T08:58:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32 2026-09-23T08:56:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/fullgoal-fund-management-co-ltd-fullgoal-hang-seng-biotech-index-etf-159132-sz-i-566836e7c8e4c8f8 2026-09-23T08:56:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/innovation-must-remain-at-the-heart-of-pandemic-prevention-preparedness-and-resp-3432662b985a1270 2026-09-23T08:22:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/vaccine-update-issue-376-september-2026-d78aba8959192ee6 2026-09-23T08:19:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/top-10-pharmaceutical-manufacturing-leaders-bfa3f2c240dbd84f 2026-09-23T08:18:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/testo-at-cphi-2026-in-milan-digital-monitoring-for-the-pharmaceutical-industry-51206cd2f0198a2f 2026-09-23T08:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/redweiler-480g-red-punch-redweiler-480g-orange-redweiler-480g-cola-tcm-120-mega-f98b8409bad1dcce 2026-09-23T07:53:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/roche-s-phase-3-win-tees-up-fight-with-novartis-for-blockbuster-kidney-disease-m-bcdf360813c716a3 2026-09-23T07:50:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/annual-flu-programme-8d7750db1c23f662 2026-09-23T07:48:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/medienmitteilung-die-bevolkerung-erwartet-einen-besseren-zugang-zu-innovativen-m-f83c269f70b8021f 2026-09-23T07:14:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/ionis-otsuka-s-phase-3-win-in-als-subtype-boehringer-s-up-to-1b-cancer-deal-c9153ce71a34dadf 2026-09-23T07:01:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/anaconda-biomed-snares-56m-in-funding-for-endovascular-tech-ec4619246ad794d9 2026-09-23T07:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-lifts-clinical-hold-on-simufilam-for-tsc-related-epilepsy-study-eca3143a8c42883f 2026-09-23T06:54:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/barzolvolimab-meets-all-primary-and-key-secondary-endpoints-in-phase-3-csu-trial-aaa1c6a5ed41a8da 2026-09-23T06:53:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/cbl-514-meets-primary-endpoint-in-phase-2-dercum-s-disease-trial-4aa1315c77b554dc 2026-09-23T06:53:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/roche-s-sefaxersen-meets-primary-endpoint-in-phase-3-igan-study-8446d6133f8aa4ca 2026-09-23T06:53:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/denmark-s-central-bank-sees-4-gdp-growth-in-2026-boosted-by-pharmaceutical-indus-ae01f315cf303771 2026-09-23T06:44:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/wednesday-newspaper-round-up-state-pension-pharmaceutical-companies-bmw-22f669ea94e5958f 2026-09-23T06:05:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-kidney-disease-can-progress-to-kidney-failure-in-up-to-half-of-patients-within-b504c1b48ca0f4bd 2026-09-23T05:53:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/argenx-arrowhead-incyte-and-other-moonshot-biotech-stocks-to-watch-6bcfcd137294b001 2026-09-23T05:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/blood-stained-ice-found-at-gallops-in-mumbai-restaurant-deepika-padukone-hosted-d7c8d4be6fe7ad46 2026-09-23T05:41:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/hhs-unveils-new-initiatives-to-reduce-animal-testing-in-drug-development-dcfb867919371bdd 2026-09-23T05:18:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/positive-interim-data-shows-roche-s-sefaxersen-significantly-reduces-proteinuria-18f5014a922c38ad 2026-09-23T05:15:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/roche-proposes-former-takeda-ceo-for-board-seat-904ade392ec97c62 2026-09-23T05:12:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pfizer-india-speaks-up-after-karnataka-fda-crackdown-says-patient-safety-is-top-2d42ea33dec63e93 2026-09-23T05:07:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/change-in-roche-s-board-of-directors-3f66dadd4f0ce683 2026-09-23T05:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-is-incyte-s-stock-performance-compared-to-other-biotech-stocks-217f74a05b95f6c6 2026-09-23T04:53:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-is-incyte-s-stock-performance-compared-to-other-biotech-stocks-31a60ba7548325a7 2026-09-23T04:53:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/varda-space-industries-signs-steve-layne-as-chief-revenue-officer-and-aaron-hube-c7f0826d164cee9b 2026-09-23T04:37:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-s-surging-biotech-sector-represents-both-competition-and-lifeline-for-the-3c127d71cc0c9a1e 2026-09-23T04:23:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-clinical-trials-give-biotech-edge-us-concerns-grow-news-and-statistics-0f3c5f350061d556 2026-09-23T04:03:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-is-one-area-where-the-us-can-afford-to-let-china-flourish-804a8a8a2ecb3155 2026-09-23T04:00:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/early-alert-ventilator-issue-from-react-health-4555c2f71c7babb4 2026-09-23T04:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/early-alert-heart-pump-controller-issue-from-abiomed-58b5f7dbc0aead0f 2026-09-23T04:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/guggenheim-names-top-stock-pick-in-biotech-sector-b71fce6a39b3f0f4 2026-09-23T03:49:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/pca-girls-varsity-volleyball-vs-biotech-senior-32c8f64109110091 2026-09-23T03:45:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-share-market-update-pharmaceutical-stocks-surge-broadly-cansino-biologics-rise-8cc39d37a45eb156 2026-09-23T03:40:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/tailwind-biotech-wins-dkk-0-7m-innobooster-grant-9b2a13b8bb0fe6d2 2026-09-23T03:11:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-fake-drug-case-pfizer-issues-statement-after-fda-revokes-licenses-of-1-21bf72b4a7e780a2 2026-09-23T03:05:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/better-healthcare-etf-invesco-s-biotech-focused-ibbq-vs-ishares-broad-iyh-cf62d79b13533fb7 2026-09-23T03:04:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/dementia-biotech-kinoxis-raises-6-75-million-with-a-2-5m-grant-as-cherry-on-top-75874c1badfd9fdd 2026-09-23T02:44:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/jeil-pharmaceutical-s-onconic-begins-phase-3-trial-in-china-for-jaqubo-injectabl-fc3a04ac114cee7e 2026-09-23T02:40:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-drugs-and-devices-have-been-on-the-market-for-years-but-fda-ordered-studies-4359a68ab4882f23 2026-09-23T02:20:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/mumbai-fda-suspends-five-food-licences-after-finding-fake-ghee-cockroaches-blood-89c6ba90f7452325 2026-09-23T02:02:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/are-clinical-trials-about-to-become-a-new-front-in-the-us-china-biotech-race-4d06a653e66fe2bd 2026-09-23T02:00:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmac-opens-recruitment-for-new-community-and-patient-advisory-committee-2a31f0e2b8d9a966 2026-09-23T02:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/onconic-s-zastaprazan-enters-phase-3-injectable-trial-in-china-c9376c3ab0540be3 2026-09-23T01:53:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/pfizer-says-patient-safety-top-priority-amid-karnataka-fake-drug-probe-6fdf8d6d60f6d15c 2026-09-23T01:52:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/young-discusses-national-security-threats-at-fdd-5b739c7bae264418 2026-09-23T00:35:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/onconic-therapeutics-launches-phase-3-clinical-trial-for-zaqubo-injectable-in-ch-5441eaf5cd51f86a 2026-09-23T00:14:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/onconic-advances-ja-q-bo-in-china-as-phase-3-injection-starts-royalties-rise-cho-b856b83f3cc2b983 2026-09-23T00:10:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/information-zum-swissmedic-portal-release-23-09-2026-0aa465ff8cc2bb82 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/astrazeneca-filed-form-6-k-16511f0f2ac5ad4f 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/patient-protection-and-affordable-care-act-temporary-moratoria-on-certain-agent-5d843f42db06f8b8 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/center-for-scientific-review-amended-notice-of-meeting-9d0893d801a68de3 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-institute-of-neurological-disorders-and-stroke-notice-of-closed-meeting-1fac41b8e10220fb 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/government-owned-inventions-availability-for-licensing-bc642d60aa107458 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sanjay-kumar-final-debarment-order-b205422749fd0e88 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/schedules-of-controlled-substances-placement-of-4-hydroxy-n-n-diisopropyltryptam-4e3caa3036ced2d5 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/importance-of-eating-dinner-as-a-family-92246a91af7931c3 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/carson-valley-health-becomes-cleveland-clinic-connected-member-174093ab24c60298 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/three-year-follow-up-of-the-randomized-trial-comparing-open-versus-laparoscopic-95fac763305e58a2 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-biochemical-responses-to-sglt2-sodium-glucose-cotransporter-2-inhib-7adc369689ad7377 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/digital-blueprint-to-traditional-craftsmanship-rehabilitation-of-atraumatic-maxi-b15c1c90f65e1e61 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/coping-strategies-among-early-phase-cancer-clinical-trial-participants-6d40b1b740992c12 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/peer-review-report-for-impact-of-pharmacist-involvement-in-antimicrobial-steward-b6da4337dc8c16fc 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/kidney-transplantation-in-patients-over-80-years-of-age-clinical-opportunity-eth-609ac733fe0515e3 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/trefoil-technique-in-cryoballoon-isolation-of-the-left-common-pulmonary-vein-tru-9ab9b4bb159c12bf 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-effect-of-a-fortified-date-bar-on-perceived-stress-and-morning-salivary-cort-795cb59bd9f91736 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/neck-disability-associated-factors-and-quality-of-life-among-physiotherapists-in-49a201e66e78e7eb 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/postoperative-c-reactive-protein-as-a-marker-of-the-early-inflammatory-response-875ae85d2ce71266 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/short-term-safety-of-gastric-endoscopic-submucosal-dissection-in-patients-aged-8-4db1fa7ffa8f382b 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-multidimensional-assessment-of-cardiometabolic-risk-in-asian-americans-with-ch-03ad6b21bec4495c 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/general-hiv-related-knowledge-and-attitudes-among-nurses-and-nursing-students-a-c6efa7106a99e37c 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cannabinoids-in-diabetes-integrating-scientometric-trends-with-mechanistic-pharm-39278e405c2b26f7 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrative-analysis-of-atp2b4-expression-and-its-clinical-and-molecular-associa-930117645916a86d 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-acquisition-quantifying-the-annual-carrying-cost-of-long-term-biospecimen-b9123924b47e7a6c 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/paraprobiotics-and-postbiotics-from-mechanistic-evidence-to-food-applications-an-8f9399cd6bdd47cc 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/editorial-explainable-artificial-intelligence-for-trustworthy-and-human-centric-ac82feba19738eaa 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-between-role-stress-and-job-burnout-among-clinical-research-nurses-a-b5aa08fccae4bfd4 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/therapist-self-report-reliability-and-accuracy-in-individual-vs-conjoint-systemi-e555b020dd335edd 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/optimal-prophylaxis-for-perioperative-drug-induced-delayed-neurocognitive-recove-5ca2615ca4e7f295 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/short-term-clinical-outcomes-associated-with-a-standardized-multicomponent-facia-e1801e946690bdbb 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/efficacy-of-anticoagulation-therapy-in-elderly-patients-with-clinically-diagnose-de416e1a65baf3d8 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-multimodal-machine-learning-diagnostic-model-for-alzheimer-s-disease-integrati-226cd8e46b6e3b46 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biological-characterization-of-a-clinical-human-adenovirus-type-3-isolate-with-o-cdfc8156c517f734 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-retrospective-cohort-study-predictive-nomogram-for-clinical-pregnancy-outcomes-3525205333fa2902 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-impact-of-early-enteral-nutrition-support-on-gastrointestinal-function-abe6b8b27c7ff208 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/editorial-cellular-metabolism-the-immune-system-and-oncogenesis-opportunities-fo-f6f882b45b14e4b6 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-epidemiological-profile-of-hospitalized-patients-with-leptospirosis-b7104dcb13cec58b 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/metabolic-and-anthropometric-predictors-of-paediatric-metabolic-steatotic-liver-c04828fdbc62dda2 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/safety-and-efficacy-of-whole-body-chlorhexidine-gluconate-cleansingwith-or-witho-bf1520c4fa2ebd4f 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/uptake-barriers-and-facilitators-of-open-science-in-clinical-psychology-findings-e79006e53d98c6de 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-care-contributes-to-tuberculosis-treatment-adherence-and-drug-saf-c97458518d1fd4b2 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-review-of-nanostructured-lipid-carriers-nlcs-and-their-applications-in-pharmac-4190dcc03c58cab9 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-and-optimization-of-an-rt-qpcr-assay-for-determining-mirna-1202-expr-f465d5014a63c6eb 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/addictive-escapism-in-the-context-of-fragmentation-of-value-semantic-space-drug-39c30a45b7c82bb5 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/peer-review-report-for-effect-of-a-community-based-intervention-for-cardiovascul-bffd3e087f4f828c 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/impact-of-timing-of-presentation-and-laparoscopic-findings-on-clinical-outcomes-99b32a220658c2ef 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-aimsi-protocol-study-protocol-of-a-randomized-double-blind-non-inferiority-c-0d2f973c86632267 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-four-tier-anti-hcv-hcv-rna-interpretation-grid-for-risk-selected-clinical-popu-0462e6238c73bb27 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/immediate-analgesic-effect-of-cheek-acupuncture-vs-etoricoxib-for-patients-with-1f433045c616e8d5 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/recombinase-polymerase-amplification-coupled-with-crispr-cas12a-for-rapid-detect-9088f98caabcd613 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/polygenic-risk-score-enhances-comprehensive-breast-cancer-risk-assessment-and-mo-f105e2006792438e 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/treatment-status-influences-circulating-microrna-expression-and-their-clinical-a-330230b34efa50ae 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparison-of-clinical-characteristics-species-composition-and-antimicrobial-res-ad48db0c75ecfcad 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cell-free-therapies-emerging-applications-of-extracellular-vesicles-and-secretom-0eb0c307fb10fd9d 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/legal-organizational-and-financial-mechanisms-for-providing-medicines-not-includ-adcb8486b171831b 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/leveraging-long-read-sequencing-to-bridge-the-diagnostic-and-equity-gaps-in-diff-e2cbefef207ca413 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/letter-to-the-editor-from-y-lmaz-et-al-the-free-t3-free-t4-ratio-predicts-relaps-73b9efa36fc223a3 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/dna-methylation-dysregulation-in-ebv-associated-lymphoproliferative-disorders-mo-5a356c91440576fd 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-note-on-patient-follow-up-time-distribution-in-clinical-trial-simulations-with-d0133161e4e00572 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-characteristics-treatments-and-outcomes-of-patients-with-ornithine-tran-a1c88d6d32ef3a51 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/adherence-to-treat-to-target-recommendations-in-juvenile-idiopathic-arthritis-in-84176e3cd58018ed 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/precise-repair-of-extremity-soft-tissue-defects-using-anterolateral-thigh-flaps-ec30ab4fc6df8f00 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-clinical-need-socioeconomic-inequalities-in-access-to-hospital-at-home-am-7c521189ed269087 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/i-invited-commentary-on-i-kandathil-et-al-s-postoperative-pain-management-in-rhi-658daec99b991957 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/phenolic-mannich-bases-review-on-synthetic-aspects-and-biological-activity-profi-61a6f71ecb860f68 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/red-blood-cell-aggregation-and-atherosclerosis-curvilinear-clinical-implications-ef768b300cdbacbe 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluation-of-eating-disorders-in-relation-to-premenstrual-syndrome-in-adolescen-c0244b80e5002d85 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/defining-near-term-treatment-goals-for-benzodiazepine-use-in-clinical-practice-04a3e19325e3d4f7 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-next-frontier-in-quantitative-co-clinical-imaging-to-advance-functional-prec-ee218ea96855a1a9 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-utility-of-whole-genome-sequencing-in-identifying-a-rare-i-mycobacteriu-94f0e27ffb6f1678 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-efficacy-and-mechanisms-of-scp-ziyushuang-scp-an-anti-skin-aging-formul-dcb5b530a46d9958 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-evaluation-of-ambient-digital-scribe-systems-in-clinical-documentati-7e52ee06c03a15d9 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/reduced-antibiotic-exposure-is-not-equivalent-to-reduced-antibiotic-overuse-afte-befc1cf0c44de4bf 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fully-ablative-co2-laser-excision-of-cutaneous-lesions-a-case-series-including-p-61eadbc7ce6135fa 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tolerance-of-methotrexate-co-administered-with-pegloticase-in-patients-with-unco-7f3259a1243d82b3 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-clinical-benefit-of-routine-pet-ct-imaging-in-asymptomatic-head-and-neck-squ-a01c2272b379ada0 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/practical-lessons-in-the-global-scaling-of-clinical-ai-from-one-hospital-to-over-d823dc98459196b5 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/systemic-and-mucosal-antibody-responses-against-neisseria-gonorrhoeae-ng-outer-m-7a0211afbe545718 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-efficacy-and-safety-of-cd19-chimeric-antigen-receptor-t-cell-therapy-bc4ebc4c756dba65 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/synthetic-lethality-in-cancer-mechanisms-therapeutic-exploitation-and-clinical-t-1f3bebf9bae27ae3 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/asymmetrical-consent-in-ambient-clinical-ai-rethinking-patient-recording-rights-e70ad24154760143 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/carotid-intima-media-thickness-in-beta-thalassemia-a-systematic-review-and-meta-305f74b84c51fd60 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/predictors-of-morbidity-and-mortality-in-malignancy-related-ascitic-fluid-infect-d88edb300cf290a3 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmacotherapy-of-irritable-bowel-syndrome-with-constipation-in-children-an-upd-afbf506f2debfc3c 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-preoperative-pain-neuroscience-education-on-pain-catastrophizing-and-e-421cbac901807b13 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluating-patient-reported-outcome-measurement-in-fibromyalgia-clinical-trials-a645cfade04ad851 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/professional-socialization-and-competency-based-role-development-in-clinical-eth-8af2a02fe55fbcbc 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agentic-ai-in-medicine-challenges-for-responsible-development-and-the-case-for-c-26ffe98b6e3b2465 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/performance-status-over-chronology-determinants-of-curative-versus-palliative-tr-13b5296c766e71c2 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/improving-adaptation-in-male-high-altitude-workers-through-pressurization-a-rand-5bafac1786fd222c 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ranibizumab-port-delivery-system-for-neovascular-age-related-macular-degeneratio-d7aa2ef6ee7adaae 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/procomb-a-practical-and-robust-design-with-randomization-to-optimize-dose-combin-290fbb808edc5459 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/impact-of-sickle-cell-hemoglobin-genotypes-on-clinical-outcomes-among-i-plasmodi-d38e4ae0b0ee8c10 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-biological-mechanisms-to-causal-inference-quantitative-systems-pharmacology-3681a18664af4d7e 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/volumetric-modulated-arc-therapy-for-lung-cancer-correlation-between-dose-and-vo-6490752166bf0195 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/transvaginal-drainage-vs-laparoscopy-for-tubo-ovarian-abscess-6cbf99995376ed2c 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07837336-an-evaluation-of-nutritional-status-body-composition-and-dietary-int-ac0a45c501a1eb6d 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07837089-increasing-engagement-with-digital-behavioral-health-ef6671fec5e10550 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07836764-validation-of-1-minute-sit-to-stand-test-for-assessment-of-breathles-8859db9c2c87a48e 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07836738-effect-of-stellate-ganglion-block-on-sleep-quality-in-patients-with-5b8e8e776e4c1c8d 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07836686-clinical-and-radiographic-success-of-modified-lstr-techniques-in-pri-6cb9d89901a63027 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07836452-a-phase-1-first-in-human-study-of-city-rbp4-in-healthy-volunteers-an-37c0c1ff6e99544a 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07836439-comparing-graston-technique-and-diacutaneous-fibrolysis-for-pain-dis-e09cd2476cb3651f 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07836205-brain-activity-and-changes-in-consciousness-during-general-anesthesi-b453ee4141f9c01a 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07836101-study-of-sarilumab-with-immune-checkpoint-inhibitor-rechallenge-in-p-2356a03863440eaa 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07836088-a-clinical-study-on-using-multimodal-ultrasound-to-assess-muscle-mas-7d4fef44519e2a4f 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07836036-evaluation-of-ras-inhibitor-treatment-in-participants-with-advanced-97efdfb4531195db 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07835997-radicle-relaxationtm-cix-a-study-assessing-the-impact-of-health-and-934bffecad7e6f1a 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07835945-comparison-of-arterial-and-capillary-blood-gas-analyses-in-patients-529f238adbd0acd5 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07830212-diagnostic-performance-of-acp3-targeted-pet-imaging-in-patients-with-565d43acb3c87207 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07830173-effects-of-task-oriented-training-on-balance-with-or-without-texture-3015b6561b54636c 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07825857-randomized-controlled-trial-of-tirzepatide-for-methamphetamine-use-d-23e6cd17cc91d8df 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07678606-association-between-4d-mri-parameters-and-the-clinical-characteristi-96a7cb0cf013b2e6 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07661810-patient-controlled-remimazolam-sedation-under-spinal-anesthesia-137f2a8674e26ee0 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07643922-endovascular-therapy-for-cerebral-vasospasm-after-aneurysmal-subarac-8f6d74f8cf9d0947 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07631377-the-lalelalung-study-digital-stethoscope-clinical-evaluation-beb6ad86a49511a4 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07610395-trial-comparing-the-safety-and-efficacy-of-two-different-oral-vpv-do-87a303f89eb88c16 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07549321-a-safety-and-efficacy-study-of-hu14-in-high-risk-neuroblastoma-patie-43b06e17d6f6ecf0 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07530705-efficacy-and-safety-of-subcutaneous-injection-of-xh-02-in-the-treatm-f412cd4960e5cf43 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07527052-emerging-technologies-and-teen-mental-health-1ddeb4440ccb88cf 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07522944-ai-guided-personalized-relaxation-for-hemodialysis-patients-a62638bab807b3f4 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07518407-dietary-insights-and-nutritional-education-in-adults-on-glp-1-therap-4dec0f2fe0a882e7 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07502352-remotely-delivered-cognitive-behavioral-stress-management-for-breast-91150ea8bc706ee0 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07388550-phase-i-open-label-safety-trial-of-pembrolizumab-for-neurological-po-c8883fe8549f9913 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07343024-methods-of-identifying-effective-off-guideline-treatments-for-advanc-ca2a1b38930bebd7 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07242300-efficacy-and-safety-of-recombinant-botulinum-toxin-type-a-eveotox-fo-045a31d11416acd0 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07237295-communityrx-kidney-health-d9146459a64c0ff2 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07225075-pivotal-study-of-the-silk-vista-baby-flow-diverters-in-the-treatment-bc87ac8f8819f15d 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07169630-pet-imaging-of-phosphodiesterase-4-pde4-in-volunteers-with-alzheimer-ad9bf3a66aac9969 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07156175-a-study-to-investigate-the-efficacy-and-safety-of-sar444336-in-adult-b02814ea75fb9a86 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07094412-patient-engaged-development-and-testing-of-educational-content-on-si-27ba66199a75081e 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07087249-feasibility-and-preliminary-effects-of-a-therapeutic-approach-using-d219d987db0fd1a3 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07005297-clinical-genetics-branch-eligibility-screening-survey-e7dec4054d0f1b0f 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06926283-a-study-of-dxc008-in-patients-with-prostate-cancer-and-other-solid-t-2fa107a99237b6d4 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06922786-hemadsorption-to-enhance-drug-elimination-in-intoxications-84ac6507d560994b 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06878066-thrombolysis-in-factor-xa-inhibitors-trial-3f17a0f3421a802b 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06824987-dose-ranging-safety-tolerability-and-efficacy-study-of-azd2373-in-pa-92b855aa8d4ba3fa 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06774885-role-of-folic-acid-in-the-management-of-adjuvant-endocrine-therapy-i-417f6298e18d101c 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06659341-a-phase-i-study-of-bay3498264-given-together-with-sotorasib-in-parti-85034d93db98e407 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06633536-real-life-treatment-outcomes-of-ravulizumab-in-pnh-2cd6c195b7a76415 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06630013-a-new-ultrasound-score-for-swallowing-disorders-diagnosis-in-difficu-abb34b6abc54acc3 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06619587-a-study-to-evaluate-safety-pharmacokinetics-and-activity-of-gdc-7035-31c0e9a9b3d7a2cf 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06558214-optimus-prime-safety-and-feasibility-of-optune-gio-integrated-with-m-c4f3b9d8c7fc609e 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06500702-a-study-to-evaluate-the-efficacy-and-safety-of-frexalimab-brivekimig-e8eca76edaae6e69 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06389591-rna-lipid-particle-rna-lp-vaccines-for-recurrent-adult-glioblastoma-93050016a66deac6 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06305676-biomarker-approach-to-screening-for-the-early-detection-of-hpv-relat-104230ccfe36130b 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06014489-a-trial-to-assess-cobicistat-boosted-venetoclax-in-combination-with-e7d8687b4e0bc8c2 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05624528-a-clinical-trial-of-tolcapone-in-obsessive-compulsive-disorder-6738dd1b07616e6f 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04989504-testing-the-application-of-mepitel-film-during-radiation-therapy-to-a505af7d533aa90c 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04812925-a-phase-3-study-to-evaluate-the-safety-and-efficacy-of-efgartigimod-caa7445c3958c388 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04628767-testing-the-addition-of-medi4736-durvalumab-to-chemotherapy-before-s-d432900cd209dde8 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04591639-the-dapa-memri-trial-9f8a6fec825fbaa7 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04433455-influencing-factors-of-cerebrovascular-disease-and-cognition-in-hemo-430cbbfd790ca1de 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04400695-a-study-of-rc48-adc-for-the-treatment-of-locally-advanced-or-metasta-e349c8a3a71c2f58 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04222413-metarrestin-ml-246-in-subjects-with-metastatic-solid-tumors-fba3643f3c2c4144 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct02444936-zostavax-in-persons-imminently-receiving-chemotherapy-for-solid-orga-ddb176532249fbec 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/rocket-pharmaceuticals-rckt-gets-fda-alignment-on-heart-drug-trial-can-it-ease-s-7185c26cdd11880d 2026-09-22T23:52:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/keep-britain-working-review-update-a-national-growth-opportunity-september-2026-b449a68a7ec408e5 2026-09-22T23:01:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/as-stigma-fades-reverse-mergers-boom-in-biotech-174a6012d4b759f8 2026-09-22T22:59:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-takes-issue-with-empower-pharmacy-s-glp-1-production-in-new-warning-letter-bbcc7bc0792288c1 2026-09-22T22:48:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-overlooked-role-of-containers-in-chemical-and-pharmaceutical-operations-d9a479d7a99df2f6 2026-09-22T22:09:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/eli-lilly-breaks-ground-on-6-5b-houston-pharmaceutical-manufacturing-facility-9c9b191a0f0915cd 2026-09-22T21:44:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/novo-may-be-getting-a-better-deal-than-expected-with-medicare-s-bridge-program-0be7d11290c417d3 2026-09-22T21:22:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-s-yipin-pharmaceutical-raises-tens-of-millions-in-yuan-for-anaesthetics-pu-df3f73952434bb15 2026-09-22T21:18:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/biopharma-biological-safety-cabinets-aseptic-technique-for-sterile-drug-manufact-50ac51026318a92a 2026-09-22T20:51:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/vht-vs-xbi-is-diversified-healthcare-exposure-or-biotech-stocks-the-smarter-choi-0db424becee8ba71 2026-09-22T20:41:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/amgen-drug-meets-goals-of-key-test-in-common-autoimmune-disease-with-no-approved-562c53f4bdd9952b 2026-09-22T20:03:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/human-cell-tests-and-computer-models-gain-formal-place-in-fda-rules-for-drug-saf-4288d02f95194a5d 2026-09-22T20:00:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/celldex-therapeutics-upgraded-to-buy-after-posi-03401a823e3c1eb5 2026-09-22T19:59:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-a-precision-medicine-trial-leveraging-blood-based-tumor-genomics-832a33c89b017818 2026-09-22T19:58:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/viking-therapeutics-soars-36-on-clinical-trial-results-an-important-step-3d9507f6b4483b3a 2026-09-22T19:55:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-european-african-vaccine-initiative-eavi-accelerating-preventive-450f5665b25341fd 2026-09-22T19:55:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-services-for-environmental-exposure-and-health-assessment-in-euro-53b48a7be88525ab 2026-09-22T19:54:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/on-the-job-training-program-helps-greenwood-resident-into-biotech-career-811eb59219a9358c 2026-09-22T19:53:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/direxion-daily-s-p-biotech-bear-3x-shares-declares-quarterly-distribution-of-0-0-ccfddfb80ed3a79a 2026-09-22T19:52:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/ulefnersen-meets-primary-end-point-in-phase-3-fusion-trial-for-fus-als-004c41caee9d8e4e 2026-09-22T19:41:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/legend-biotech-nasdaq-legn-shareholder-plans-2-715-ads-rule-144-sale-841a12d86e050982 2026-09-22T19:31:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/amgen-reports-a-phase-3-win-with-sjogren-s-drug-candidate-4d19987a7b90f4bd 2026-09-22T19:06:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/major-nj-pharmaceutical-company-lays-off-hundreds-9bb21c3e4fe5cb52 2026-09-22T19:03:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/nine-european-drugmakers-note-concern-over-region-s-pharma-investments-pharmexec-d2f1bdf40f76425d 2026-09-22T19:02:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/european-drugmakers-say-they-are-losing-ground-to-us-and-chinese-rivals-0d402f8f3ef33843 2026-09-22T18:51:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/former-legend-biotech-nasdaq-legn-officer-lines-up-1-3m-stock-sale-a09773669bac8e93 2026-09-22T18:34:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/veraxa-biotech-vrxa-builds-oncology-pipeline-around-bitac-platform-public-market-f355446610826911 2026-09-22T18:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/did-ceo-appointment-just-shift-legend-biotech-stock-investment-narrative-39b39a15e61896b9 2026-09-22T18:06:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/caris-life-sciences-coasts-past-a-buy-point-why-this-texas-biotech-researcher-de-bc7b2a82a6bfdea0 2026-09-22T18:01:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-updates-rules-to-advance-non-animal-innovative-testing-in-human-drug-develop-c6422f067acfdab8 2026-09-22T17:47:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-secures-new-radioligand-in-900m-deal-as-competition-strengthens-50d67d023b86cc61 2026-09-22T17:22:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-representative-clinical-research-advancing-inclusivity-in-europe-ce5cc956533fb572 2026-09-22T17:18:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-suspends-assistant-drug-controller-over-alleged-lapses-in-counterfeit-954ba4d2ecda5f99 2026-09-22T17:01:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-an-innovative-analytical-platform-to-investigate-the-effect-and-t-22d02dfce8336ab4 2026-09-22T16:48:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-autism-innovative-medicine-studies-2-trials-36292d3d44288306 2026-09-22T16:48:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/vertex-s-kidney-drug-success-sparks-a-22-surge-for-this-rival-biotech-860d4568cb022503 2026-09-22T16:46:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-modernizes-drug-regulations-to-formalize-support-for-nams-7dde384d2183288c 2026-09-22T16:15:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/fake-medicine-racket-assistant-drug-controller-omkareshwar-suspended-aa6b284cdda1363b 2026-09-22T15:57:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-updates-rule-on-animal-testing-for-new-drugs-98a07a874a31de1b 2026-09-22T15:52:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/food-drug-crackdowns-test-india-s-regulatory-enforcement-muscle-ba2109dbf55a7346 2026-09-22T15:48:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-updates-drug-safety-testing-rules-to-embrace-non-animal-methods-cedfedd050abc998 2026-09-22T15:38:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/generic-drug-user-fee-reauthorization-amidst-alleged-concerns-of-safety-and-effi-c661778b45f1c06e 2026-09-22T15:38:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-participates-in-ustr-s-section-301-investigation-into-germany-to-address-e44e409ff6d1d1c8 2026-09-22T15:36:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-temperature-control-is-now-pharma-s-make-or-break-variable-0b39008986dae1a7 2026-09-22T15:34:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/rs-5-05-crore-spurious-drug-racket-case-24-pharma-licences-16-cancelled-and-8-su-2a0c3f8f2c032d62 2026-09-22T15:20:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/zealand-pharma-announces-initiation-of-the-registrational-phase-3-zupreme-progra-478c3cbbf4c8be0c 2026-09-22T15:15:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/amgen-inc-stock-amgn-moved-up-by-3-90-on-sep-22-facts-behind-the-movement-638e1517a3957b7d 2026-09-22T15:15:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/notifiable-diseases-causative-agents-reports-for-2026-32900b46450305d4 2026-09-22T15:06:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/rotavirus-vaccination-programme-information-for-healthcare-practitioners-53785302d776c5f3 2026-09-22T15:00:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/5-reasons-to-have-your-flu-vaccine-when-pregnant-poster-617282f23f9f2cc4 2026-09-22T14:59:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/ukhsa-spend-over-25-000-2026-a8b4b8d9bbff80c2 2026-09-22T14:58:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/antimicrobial-resistance-awareness-toolkit-for-healthcare-providers-0c0f57c6f41d20ce 2026-09-22T14:56:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/should-you-buy-moderna-stock-why-many-wall-street-analysts-say-no-9e67b14c2180f083 2026-09-22T14:53:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/4-biotech-stocks-with-key-clinical-readouts-expected-this-fall-fdfbfae8d3ac9708 2026-09-22T14:51:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-takeda-s-orzeyful-as-first-drug-to-treat-narcolepsy-type-1-cause-49d3fb93ffe19a13 2026-09-22T14:43:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/nvidia-backed-iambic-files-for-ipo-disclosing-new-clinic-and-dealmaking-details-9081c31813b92024 2026-09-22T14:37:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/2026-ipo-blitz-continues-with-4-new-biotech-filings-347251671248c048 2026-09-22T14:23:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/amgen-s-horizon-acquired-fusion-protein-eases-sjogren-s-severity-in-ph-3-win-fabca74fb5c275a3 2026-09-22T14:20:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/ukhsa-and-pace-make-new-bacteria-available-to-support-research-into-tackling-ant-03949b464e5bf1c5 2026-09-22T14:19:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/new-preliminary-positive-data-from-open-label-extension-of-phase-3-study-fasedie-a43f8824c131b981 2026-09-22T14:14:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-stakeholders-can-avert-340b-rebate-disruption-766ebeb8cd517505 2026-09-22T14:14:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/ionis-announces-positive-topline-results-from-phase-3-fusion-study-of-ulefnersen-772a4e1e1109bf31 2026-09-22T14:11:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/otsuka-announces-transformative-phase-3-fusion-results-for-ulefnersen-bringing-t-b70c8b2f7386a8a2 2026-09-22T14:11:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/travere-ceo-eric-dube-to-step-down-after-transforming-the-rare-disease-biotech-89bdf641a2b15d7c 2026-09-22T14:10:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/vertex-s-midstage-data-amplify-kidney-disease-market-opportunity-523fc055ccc416fc 2026-09-22T14:09:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-alerts-and-statements-65b7066201a76f64 2026-09-22T14:07:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-publishes-2026-food-code-c8977096a5309312 2026-09-22T14:07:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/merck-sued-with-former-lot-network-canon-patent-by-biotech-npe-181c0bc7aa670f0e 2026-09-22T14:03:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/changes-to-the-definition-of-deprivation-of-liberty-6ef57301ec10516e 2026-09-22T13:52:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-is-ibogaine-all-about-the-psychoactive-drug-presley-gerber-took-for-treatme-10da3bcc8d406517 2026-09-22T13:52:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/x-chem-announces-phase-3-milestone-in-collaboration-with-relay-therapeutics-2ed0320843199e26 2026-09-22T13:51:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-the-classroom-to-research-rethinking-school-non-attendance-as-a-complex-pub-370891176b9691ed 2026-09-22T13:47:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/roche-obesity-drug-enicepatide-delivers-15-5-weight-loss-in-phase-2-diabetes-tri-456c0904bdf4161e 2026-09-22T13:42:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/amgen-s-dazodalibep-phase-3-trial-clears-sjogren-s-hurdle-ce20313f496b35b5 2026-09-22T13:32:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-proposed-law-could-give-qualifying-botanical-drugs-12-years-of-market-exclusiv-49f868a028738c3d 2026-09-22T13:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comienza-en-lisboa-el-xv-encuentro-de-la-red-eami-con-el-objetivo-de-establecer-a43077edfe8b6ead 2026-09-22T13:23:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/otsuka-heads-to-fda-as-ionis-partnered-als-drug-hits-primary-phase-3-endpoint-7548c69d954fe247 2026-09-22T13:22:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/optimi-health-appoints-dr-michael-blough-as-chief-clinical-development-officer-d976afbd9022e8d7 2026-09-22T13:15:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/tb-bcg-and-your-baby-74fb0616222bda49 2026-09-22T13:05:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/amgen-announces-positive-topline-phase-3-results-for-dazodalibep-in-moderate-to-6063bc2e687b62fc 2026-09-22T13:05:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/sjogren-s-disease-has-no-fda-approved-medicines-amgen-s-treatment-improved-disea-be1c1e5896371af6 2026-09-22T13:02:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/psychedelic-depression-and-ptsd-trials-get-new-lead-at-optimi-health-opth-41c95a683e26fe4e 2026-09-22T13:00:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/amgen-announces-positive-topline-phase-3-results-for-dazodalibep-in-moderate-to-1ba12e27f284c0f1 2026-09-22T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/optimi-health-appoints-dr-michael-blough-as-chief-clinical-development-officer-b962f1ca3661de64 2026-09-22T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-lung-cancer-treatment-showed-90-5-disease-control-in-an-interim-trial-assessme-65b591b14180f7f7 2026-09-22T12:47:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/maia-biotechnology-reports-pivotal-phase-3-clinical-trial-progress-in-advanced-n-d50277e15a8ec3c4 2026-09-22T12:47:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/preliminary-data-social-anxiety-scores-improved-31-points-in-four-months-with-vi-c63a4ba9a63823a2 2026-09-22T12:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/wisner-baum-investigates-generic-drug-quality-as-2026-patent-cliff-accelerates-c-579b2debb3e49258 2026-09-22T12:19:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/wisner-baum-investigates-generic-drug-quality-as-2026-patent-cliff-accelerates-c-6d1013a4bee3ce65 2026-09-22T12:18:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/otsuka-announces-transformative-phase-3-fusion-results-for-ulefnersen-bringing-t-d5ff980a261f735c 2026-09-22T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/claros-technologies-announces-continued-commercial-expansion-into-europe-and-ent-21dc3bd5985bea1b 2026-09-22T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/allergan-aesthetics-debuts-aa-signaturetm-in-the-united-states-with-skin360-its-3fb68c46a13552f5 2026-09-22T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/one-rare-seizure-disorder-has-no-approved-treatments-a-trial-has-dosed-its-first-8857792eb4fd05eb 2026-09-22T11:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/phase-3-depression-data-could-define-the-case-for-cybin-stock-bf3ee7c531131e23 2026-09-22T11:25:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/newron-presents-h1-2026-results-and-provides-corporate-update-12c4c38dc6d0be1a 2026-09-22T11:24:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/celldex-reports-positive-phase-3-results-for-barzolvolimab-in-chronic-spontaneou-0017f5ea9d432ed0 2026-09-22T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/celldex-announces-positive-results-from-phase-3-embarq-csu1-c8dfd9af985de52b 2026-09-22T10:58:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bofa-securities-names-top-biotech-stock-amid-sector-rally-65a732f8b3124bfc 2026-09-22T10:56:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-merck-drug-cut-the-risk-of-worsening-disease-by-76-the-fda-updated-its-label-35639d1ef2653d3e 2026-09-22T10:50:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-phenylephrine-hydrochloride-prices-hold-firm-as-q4-pharmaceutical-demand-stre-0149dcbbdb4b1dc3 2026-09-22T10:46:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/u-s-fda-approves-update-to-the-label-for-winrevairtm-sotatercept-csrk-to-include-d63bea0d0db63aa3 2026-09-22T10:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/u-s-fda-approves-update-to-the-label-for-winrevairtm-sotatercept-csrk-to-include-e2755dc1ca6275fc 2026-09-22T10:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-trials-for-medicines-good-clinical-practice-inspections-68a2c21adf64b7b1 2026-09-22T10:42:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-drugs-and-devices-have-been-on-the-market-for-years-but-fda-ordered-studies-f39731160de90db0 2026-09-22T10:37:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/nearly-600-fda-postmarket-drug-studies-are-behind-schedule-while-many-of-the-med-f28350f4fcac615b 2026-09-22T10:15:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-admet-ai-for-medicines-safety-survey-a86c0a5b77beeed2 2026-09-22T10:00:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/harmoni-gi1-a-phase-iii-trial-featuring-ivonescimab-plus-chemotherapy-compared-t-5397d986a24a195a 2026-09-22T10:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/direct-nitrite-analysis-simplifies-tests-of-pharmaceutical-excipients-for-risk-c-4b362d430ed610ea 2026-09-22T10:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-drugs-and-devices-have-been-on-the-market-for-years-but-fda-ordered-studies-2b9ea682e34169f8 2026-09-22T09:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/regulatory-round-up-22-september-2026-5ba9abe7a8a91f88 2026-09-22T09:23:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/mannkind-corporation-mnkd-stock-analysis-exploring-a-127-68-potential-upside-in-88d42183e45cec68 2026-09-22T09:21:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/book-review-the-age-of-cures-by-barry-werth-50b9ec628976b5a2 2026-09-22T09:00:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/boryung-signs-277-mil-taxotere-supply-deal-with-china-s-yifan-6f397d63d69e2daf 2026-09-22T08:37:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/reg-hikma-pharmaceutical-director-pdmr-shareholding-bb695b3e1242f838 2026-09-22T08:32:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/ukhsa-and-university-of-oxford-scientists-uncover-genetic-changes-in-the-bacteri-619305ae10369373 2026-09-22T08:30:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/voluntary-scheme-aggregate-net-sales-and-payment-information-august-2026-1002643f3a56701e 2026-09-22T08:30:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/vpag-quarterly-net-sales-and-payment-information-e87d48f3b7220662 2026-09-22T08:30:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/chemical-hazards-compendium-2cf1a7b32dba1e24 2026-09-22T08:30:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-health-impacts-from-industrial-sources-of-pfas-a-rapid-review-ed4c661ce7265e41 2026-09-22T08:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/per-and-polyfluoroalkyl-substances-pfas-general-information-49da969af76edf3b 2026-09-22T08:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hanyang-precision-chairman-countersues-former-hanmi-pharmaceutical-executives-29f8aa0fd33812f7 2026-09-22T08:20:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-s-2026-single-trial-default-standard-reframes-the-dual-pivotal-debate-for-sp-db564c899dadd3aa 2026-09-22T07:55:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/submicron-ir-for-pharmaceutical-research-development-and-quality-f91eaac67fdb6ecb 2026-09-22T07:44:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sant-98561788d726bcd6 2026-09-22T07:40:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/greece-to-prioritise-biosimilars-legislation-during-2027-eu-presidency-says-mini-7c952cb632ab6e86 2026-09-22T07:33:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/mayer-brown-represents-underwriters-on-teva-pharmaceutical-s-us-4-9-billion-seni-c8c0fec7c979c997 2026-09-22T07:28:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/iambic-maintains-momentum-from-string-of-big-pharma-partnerships-by-aiming-for-i-14246701c70fe37f 2026-09-22T07:14:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/trevi-therapeutics-stock-trades-at-usd-14-71-as-biotech-data-matters-663f1d5418a1fc34 2026-09-22T07:13:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-aspen-s-priyen-naidu-drives-a-human-centred-approach-to-technology-f2ab4450d8792b6a 2026-09-22T07:10:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/bank-of-america-corp-de-invests-38-35-million-in-ultragenyx-pharmaceutical-inc-r-127cbc20e446c4bf 2026-09-22T07:10:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/building-on-success-ipsen-receives-two-new-gold-brandon-hall-awards-d9486765e1c17bb8 2026-09-22T07:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/merry-life-biomedical-starts-phase-2-trial-of-tml-6-for-early-alzheimer-s-045429441a897961 2026-09-22T06:45:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/ec-approves-obicetrapib-as-oral-cetp-inhibitor-for-hypercholesterolemia-ae296af74503e57a 2026-09-22T06:40:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-updates-nonclinical-testing-regulations-140133928ca7c94d 2026-09-22T06:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-clinical-endpoints-rethinking-als-drug-development-through-disease-biolog-b7cd7818b37e9411 2026-09-22T06:05:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-tre-cadbbf2157ab9b29 2026-09-22T06:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/india-s-biotech-self-reliance-moment-102921bdf8bc7232 2026-09-22T05:50:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/5-best-glp-1-stocks-for-2026-and-how-to-invest-99408731658b95c2 2026-09-22T05:10:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/boryung-scores-277m-anti-cancer-drug-supply-deal-in-china-d65692bc15e5f4fc 2026-09-22T05:02:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/ad-hoc-announcement-pursuant-to-art-53-lr-roche-announces-positive-phase-ii-resu-ca3349841e8c60a5 2026-09-22T05:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/healthnet-mea-to-commercialise-comide-er-methylphenidate-er-in-uae-under-exclusi-25f7252f14d192bd 2026-09-22T05:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/child-resistant-locking-closures-market-to-2035-pharmaceutical-safety-mandates-d-ee831d2ecb1081b6 2026-09-22T04:46:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/india-news-96d7107e3a341182 2026-09-22T04:26:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-finally-moves-to-comply-with-2022-law-ending-animal-testing-mandate-3c5286ce175b5ebd 2026-09-22T04:07:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/nvidia-qia-backed-iambic-therapeutics-files-for-us-ipo-as-biotech-boom-rolls-on-478bd63e265078d4 2026-09-22T03:35:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-fda-moves-away-from-animal-testing-how-organoids-ai-organs-on-chips-could-imp-8ae12dc92c9fbd34 2026-09-22T03:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/boryung-signs-277-million-taxotere-supply-deal-with-china-s-yifan-pharmaceutical-a71b4ed4f2241099 2026-09-22T03:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/melbourne-biotech-turns-to-stem-cell-brain-models-in-alzheimer-s-push-7ea3ae37b3c8e127 2026-09-22T02:35:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/editorial-strict-checks-on-drug-supply-chain-9e99b919fddbd074 2026-09-22T02:29:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/eli-lilly-makes-another-biotech-bet-ahead-of-retatrutide-data-lly-stock-surges-t-f277b743c44c8524 2026-09-22T01:59:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/lilly-s-breast-cancer-combo-wins-approval-2625666fc10dfe92 2026-09-22T01:26:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/analysts-offer-insights-on-healthcare-companies-helus-pharma-help-ultragenyx-pha-eb82ae5a7d95e0ef 2026-09-22T01:26:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-envista-holdin-90aff1940631b27a 2026-09-22T01:10:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gc-wellbeing-and-boryung-expand-korea-hospital-use-of-livnec-injection-chosunbiz-f8357be306326357 2026-09-22T00:41:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pfizer-details-phase-3-sleep-apnea-trial-for-ex-metsera-obesity-drug-9b66bc3b08304ba5 2026-09-22T00:38:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-glp-1-users-should-know-about-the-potential-risk-of-a-rare-type-of-vision-l-d11a80ef91435ad7 2026-09-22T00:17:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/cullinan-therapeutics-inc-common-stock-cgem-stock-price-news-quote-history-9e08eae6d576bb60 2026-09-22T00:11:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gsk-filed-form-6-k-2122447c5946b5e1 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-cancer-institute-notice-of-meeting-8918f24bc0866cb9 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-e3d513e458366039 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-submission-to-omb-for-review-and-approv-774090bba85bb2af 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nonclinical-testing-terminology-5eba25885ce1826a 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-submission-to-omb-for-review-and-approv-c3c6da23622a87ae 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/submission-for-omb-review-30-day-comment-request-the-impact-and-costs-of-promoti-1981b0d77e209b56 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/center-for-scientific-review-amended-notice-of-meeting-ed0ae1132b37b44c 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-institute-of-environmental-health-sciences-notice-of-meeting-request-fo-9ec32231184cff8d 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-leader-clearlax-5db04f3e1a797e11 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/properly-fueling-your-child-for-sports-9a38989fbb516ab5 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/client-side-ephemeral-de-identification-of-protected-health-information-phi-in-m-1723769fa40654cb 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/identification-of-ca2-as-a-potential-candidate-gene-involved-in-the-therapeutic-468ef38d57294912 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/outcome-evaluation-of-percutaneous-coronary-intervention-vs-medical-therapy-alon-8c7ce15ef14f8bd4 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparison-of-3-dual-single-pill-combinations-for-blood-pressure-lowering-a-seco-109f27c8ec4ad6fe 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/lutetium-177-radiopharmaceuticals-in-cancer-care-progress-and-challenges-d843582ed6f93cf2 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/original-rdna-semaglutide-versus-synthetic-copies-differences-and-clinical-impli-ce9bab7fe2f3a574 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/real-world-drug-survival-and-treatment-outcome-of-ixekizumab-in-patients-with-sp-277345d1212fc9c3 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/long-term-efficacy-and-impact-on-rehospitalization-of-qishen-granules-in-patient-17f7306f6553327e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/case-report-acute-biliary-pancreatitis-after-semaglutide-dose-escalation-in-an-a-a60c1f8f70d97d5a 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nanoparticle-pharmacomicrobiomics-reprogramming-the-microbiome-immune-axis-for-c-19c17144a628d4ac 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-evaluation-of-mineral-trioxide-aggregate-diode-and-erbium-chromium-d-65739071b0d85441 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ai-driven-precision-targeted-therapy-for-egfr-mutant-non-small-cell-lung-cancer-b4e2bd97ff9e6410 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/regimen-stratified-bayesian-model-based-meta-analysis-of-targeted-biologics-in-g-27d0dea64c7f9ddf 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/safety-pharmacokinetics-pharmacodynamics-and-target-mediated-drug-disposition-mo-ed4b412b6f6c0ff8 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/summary-for-patients-tobacco-use-treatment-synopsis-of-the-2026-u-s-department-o-07d3fe471f477728 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hybrid-endoscopic-submucosal-dissection-enhances-efficiency-with-comparable-cura-59f35ebeba6339bc 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/advances-risks-and-implementation-challenges-of-artificial-intelligence-as-a-for-0aaebc5fc67cb1f4 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/to-what-extent-is-water-hydration-the-best-method-of-maintaining-voice-protectio-c0b14f3feb98d6fc 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/design-and-limitations-of-tumor-microenvironment-responsive-nanocarriers-for-tar-a541e35ac2a228eb 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ethical-legal-and-societal-implications-in-xenotransplantation-elsi-a-korean-reg-574b7c8e38dc1ea4 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/practicing-in-resource-limited-and-siloed-settings-b8a360d6cc716831 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/synbiotic-hqp08-supplementation-for-hair-loss-and-depressive-symptoms-an-open-la-d810c0348c9d2a53 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effectiveness-of-participatory-strategies-for-prevention-of-dengue-and-leptospir-8b622e47d75a3a2e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/early-cardiotoxicity-in-pediatric-patients-with-acute-lymphoblastic-leukemia-and-66bd0483b1ad137d 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrating-tumour-biology-into-surgical-decision-making-for-metastatic-colorect-72069f85a27f2b65 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/asparagine-synthetase-deficiency-a-novel-asns-variant-and-a-systematic-review-of-7688496f64879380 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/economic-evaluation-of-primary-health-care-integration-and-targeted-mass-drug-ad-23f6f417faae079e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-outcomes-following-a-traditional-chinese-medicine-foot-bath-preparation-71dccefa5ac0c66e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-between-post-procedural-parenteral-anticoagulation-therapy-and-clini-aa105c9902a1b506 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/thromboembolic-prophylaxis-in-childhood-idiopathic-nephrotic-syndrome-from-patho-561cd01380060c71 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultrasound-defined-fatty-liver-and-the-risk-of-progression-from-preclinical-to-c-f9a84b6d726a3f6e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hematoma-expansion-in-intracerebral-hemorrhage-neuroimaging-biomarkers-radiomics-e09c758c16081ca4 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/editorial-non-invasive-brain-stimulation-from-basic-science-to-clinical-applicat-57c6e566091c722c 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-fracture-stabilization-to-functional-recovery-a-prospective-clinical-radiol-b0de384d30fed29f 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-radiological-outcomes-after-philos-locking-plate-fixa-tion-of-proxi-6cb1d9db4ee8d196 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/magnetic-resonance-imaging-evaluation-of-oblique-injuries-introduction-of-the-de-8fc08014efbffe9e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-reproducible-framework-for-auditing-the-trustworthiness-of-clinical-machine-le-e156ce2fb89f21be 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-statistical-similarity-a-clinical-validation-framework-for-synthetic-acut-72e3848e5ab24c81 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-association-between-clinical-activity-and-inflammatory-response-in-odontogen-bd41993f007c7d9a 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effects-of-lean-beef-on-resistance-training-induced-strength-and-body-compositio-7dbccd69d52aea28 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/antioxidant-premedication-reduces-mitochondrial-and-nuclear-dna-damage-repair-in-cecfc8008ef47d6f 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ct-derived-myocardial-extracellular-volume-current-evidence-clinical-utility-and-f91615e1f0f6a045 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/early-phosphate-supplementation-after-newly-detected-hypophosphatemia-in-older-i-5ee50f7a22451580 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/associations-between-social-determinants-of-health-and-clinical-diagnosis-time-o-ba252f64579ea133 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-stroke-crisis-in-ageing-societies-global-trends-risk-factors-and-clinical-va-eebc145ad0ea6bea 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/response-by-maurer-and-fontana-to-letter-regarding-article-coramitug-a-humanized-b092e4d1b40d77b4 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparison-of-3-dual-single-pill-combinations-for-blood-pressure-lowering-a-seco-934d9095d9196874 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/psychological-pathways-from-disease-activity-to-quality-of-life-in-ulcerative-co-0133cc63b78f7bb5 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/my-unbearable-wife-gave-me-a-brain-tumor-subjective-theories-of-illness-and-reco-d9c4caf1f4a588e9 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/when-therapists-need-to-be-their-own-clients-the-influence-of-intersectional-pri-12d08479260be075 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/contributions-of-semiotic-cultural-psychology-for-interventions-in-clinical-psyc-cf12230181a710fb 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-literacy-antibiotic-use-behaviors-and-awareness-of-antimicrobial-resistan-7a7abb1fc6fe4ec9 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-impact-of-introducing-automated-plan-checking-in-radiation-therapy-effe-220fbd73db8233f8 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comment-on-effectiveness-safety-and-tolerability-of-ozenoxacin-2-lotion-vs-clind-75efa1fd26813f4c 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bacterial-outer-membrane-vesicles-in-colorectal-cancer-interdomain-communication-95e0d6534503eb25 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-between-early-systolic-blood-pressure-and-clinical-outcomes-in-non-c-69ae09590efea90e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/efficacy-of-combined-repetitive-transcranial-magnetic-stimulation-and-occupation-b74d503d8324ad1e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmacovigilance-practices-educational-interventions-and-barriers-to-reporting-535468794e77582d 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/occupational-allergies-clinical-presentation-epidemiology-diagnosis-and-preventi-d3e45acd9d403f28 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-of-a-conceptual-disease-model-of-atopic-dermatitis-using-data-from-t-b724371d717c237f 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/anti-tnf-refractory-inflammatory-bowel-disease-associated-with-a-novel-xiap-fram-b48dd066032a9779 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-cuprous-oxide-nanoparticles-green-synthesized-using-artemisia-dracuncu-cc51fb0cd6ece9b8 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-and-evaluation-of-a-hydroxyurea-loaded-invasome-hydrogel-for-enhance-994c6bdc360fa4cc 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/photocatalytic-treatment-of-organic-and-pharmaceutical-pollutants-in-wastewater-fb6ba995d39dc801 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tissue-specific-aging-clocks-map-structured-aging-modulatory-drug-score-patterns-9b721b6fd4c871b6 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/diagnostic-accuracy-amp-clinical-importance-of-ai-confidence-for-extremity-fract-cf31f9fe3c4a8ca6 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/could-previous-appendicectomy-influence-disease-expression-in-axial-spondyloarth-e9e0c066f4387e8f 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-performance-of-glass-hybrid-and-short-fiber-reinforced-composite-restor-651b546e41d9bbe2 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-interchangeability-of-22c3-and-28-8-pd-l1-assays-for-patient-selection-343e8ac84fe0cb4f 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/glaucoma-in-hospitalized-older-adults-polypharmacy-multimorbidity-and-therapy-di-fbced7d96caeaf15 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/specific-treatment-of-attr-cm-in-germany-expert-consensus-of-the-german-society-4b5e24406ecb15a6 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/regimen-stratified-bayesian-model-based-meta-analysis-of-targeted-biologics-in-g-760b3481681182f4 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/measuring-what-vlms-don-t-say-validation-metrics-hide-clinical-terminology-erasu-ad6cc70c31430f76 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/circulating-blood-biomarkers-after-traumatic-brain-injury-a-subanalysis-of-the-b-62e62e5a6d913481 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07834671-research-on-respiratory-support-decision-making-for-mechanically-ven-18f7097ea8b88c2f 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07833722-management-of-hypokalemia-in-intensive-care-patients-e3b9772dbefc93f6 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07833553-comparison-of-efficacy-of-caudal-versus-transforaminal-epidural-ster-ba6604bc010f1f4b 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07832422-ischemic-compression-and-low-level-laser-therapy-for-myofascial-low-d513a21624e08e3e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07826013-the-effect-of-horticultural-therapy-on-anxiety-and-quality-of-life-aeeb3468d1ba64e9 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07783802-a-study-of-clazakizumab-ly5724886-in-adults-with-elevated-hscrp-and-29441caf9fd10fa6 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07775313-base-edited-hematopoietic-stem-progenitor-cell-gene-therapy-for-trea-598ef3dcb0ccb96b 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07767487-a-study-of-ly4226695-in-healthy-participants-5cb65fa6ef63d898 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07737756-a-real-world-medical-chart-review-of-spinal-muscular-atrophy-patient-67bc8c57e8f46d84 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07619547-longitudinal-immunophenotyping-of-patients-with-inflammatory-bowel-d-3a796411228812d2 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07507760-oral-decitabine-plus-ivosidenib-as-first-line-for-older-unfit-adult-72d54845c186722b 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07504601-investigating-the-analgesic-potential-of-2r-6r-hnk-in-acute-pain-in-7d802ea0b5cc5a4e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07488676-a-study-of-asp546c-in-adults-with-gastroesophageal-cancer-pancreatic-8d01bc3f698a8cf8 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07437976-a-natural-history-of-genetic-and-environmental-predictors-of-puberta-6b2ccb1e0c1c166d 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07409272-a-study-to-evaluate-the-effectiveness-and-safety-of-setidegrasib-giv-09ad5ffe87abbd3b 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07222709-a-study-to-assess-the-adverse-events-and-how-oral-abbv-1042-moves-th-19ae8bf9c118cc7b 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07222189-a-study-to-investigate-the-long-term-safety-tolerability-and-efficac-4c589d37fe3b3d76 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07137442-distinguishing-tics-and-functional-tics-using-clinical-neurophysiolo-e0a0f7cc00953d72 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07053423-a-study-to-investigate-airway-inflammation-with-dupilumab-subcutaneo-f76e86c6aa568fa4 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06948097-syk-inhibition-in-mitigating-lung-allograft-rejection-similar-a-tria-28f73f1ac769add4 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06875310-a-study-of-adagrasib-plus-pembrolizumab-plus-chemotherapy-vs-placebo-b1d1bb9e85e90d8c 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06833944-high-intensity-interval-training-in-the-treatment-of-familial-hyperc-1b8bcbea5515768a 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06828042-safety-and-efficacy-of-universal-cd19-targeting-car-t-cells-in-refra-46bf8248aff6d69d 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06641908-anti-gd2-adc-m3554-in-advanced-solid-tumors-333d9dc4d4693020 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06585787-a-study-to-evaluate-karxt-as-a-treatment-for-psychosis-associated-wi-68a1e1572e63aeec 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06453044-mosunetuzumab-and-polatuzumab-vedotin-for-the-treatment-of-patients-f92dc5572b576547 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06393452-safety-pharmacokinetics-and-efficacy-of-pp405-in-adults-with-aga-cf7ba5e394b1e7a5 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06281665-treatment-with-aspirin-after-preeclampsia-tap-trial-d452b736868de309 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06226883-a-phase-2-study-to-evaluate-morf-057-in-adults-with-moderately-to-se-5f3287f5b75539d0 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06128551-study-of-elironrasib-and-daraxonrasib-as-monotherapies-and-combinati-018bc1740e4ec72a 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06109272-a-study-to-assess-the-dose-adverse-events-and-change-in-disease-acti-3cbaca2f6fede566 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06081894-a-trial-to-evaluate-the-efficacy-and-safety-of-aficamten-compared-to-3f0db88811c38c18 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05825274-tdcs-to-treat-drug-resistant-epilepsy-75be45242a7ab4de 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05713799-trial-of-the-combination-of-alpha-lipoic-acid-and-mirabegron-in-wome-58ca62d5ec6a8459 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05564390-myelomatch-a-screening-study-to-assign-people-with-myeloid-cancer-to-24330c5ca77ac0cb 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05419024-imaging-and-biopsy-of-people-with-hiv-1-undergoing-analytic-treatmen-ba9c2ed4984d9b75 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05201066-roll-over-study-for-patients-who-have-completed-a-prior-novartis-spo-f4d66c80a684873d 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04928846-a-study-to-assess-disease-activity-and-adverse-events-of-intravenous-aad3d7c2569dbe63 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04925479-study-to-determine-the-dose-and-safety-of-asciminib-in-pediatric-pat-36818f90875f077b 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04639830-electrophysiologic-sleep-phenotyping-and-sleep-dependent-neuro-matur-f66afd5ddf8abb8d 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04384367-efficacy-and-safety-of-rizatriptan-naproxen-10-550-mg-in-the-acute-t-b4d7fed8ac67cb46 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04269902-testing-early-treatment-for-patients-with-high-risk-chronic-lymphocy-cf81092206932f4e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03766009-increasing-patients-engagement-in-breast-cancer-surgery-decision-mak-9cb70c96b7ebe325 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03602599-chronic-graft-versus-host-disease-in-the-oral-cavity-of-patients-fol-917cfe1b45e00a8d 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03459287-study-to-evaluate-the-efficacy-safety-of-the-intercept-blood-system-27fa67412869567a 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03253705-samples-from-human-subjects-to-facilitate-basic-translational-and-cl-dd8e4dde62e55019 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct02262832-compassionate-use-of-metreleptin-in-previously-treated-people-with-g-b70e5c26c71574b9 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct02116764-analysis-of-patients-treated-for-chronic-granulomatous-disease-since-9b8692f247eb9b9b 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01925196-natural-history-and-biomarkers-of-amyotrophic-lateral-sclerosis-and-85158fa590642c6d 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01857934-therapy-for-children-with-advanced-stage-neuroblastoma-4a846ae16a327054 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01247597-dicer1-related-pleuropulmonary-blastoma-cancer-predisposition-syndro-483746454e3e0819 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct00092222-virotherapy-and-natural-history-study-of-khsv-associated-multricentr-0a1ef180e9bc1d96 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct00043472-removal-of-the-ovaries-fallopian-tubes-and-ca-125-screening-to-reduc-03a60ad923366b92 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct00034424-cause-of-familial-testicular-cancer-b37185d4ec3be3ca 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct00024622-pet-scanning-in-parkinson-s-disease-db6af6973e31a489 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct00023049-genetic-analysis-of-hereditary-disorders-of-hearing-and-balance-65bd947aa9000148 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct00004847-diagnosis-of-pheochromocytoma-05c9db90843e0e42 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct00001846-collection-and-distribution-of-blood-components-from-healthy-donors-2ef5bdb84e8cdf6e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct00001595-an-investigation-of-pituitary-tumors-and-related-hypothalmic-disorde-44f1228058efa690 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct00001254-evaluating-pancreatic-tumors-in-patients-with-zollinger-ellison-synd-c749f4fce25c54a9 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sputum-based-test-may-identify-drug-targets-in-asthma-and-copd-patient-care-onli-9b7f052101582566 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/amcham-imss-deal-pledges-us-44-million-to-bring-clinical-trials-to-mexican-publi-052095dbcfb7da9a 2026-09-21T23:39:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/nice-recommends-enhertu-for-her2-low-advanced-breast-cancer-in-england-9d334852ef112a45 2026-09-21T22:50:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/drummond-warns-rubio-of-national-security-risk-in-pharmaceutical-supply-chain-5a65cb2ace796337 2026-09-21T22:48:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-recalls-and-warnings-third-glutathione-recall-issued-over-endotoxin-contamin-07b548b075a272fe 2026-09-21T22:39:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/u-s-rulemaking-chatter-lifts-hong-kong-s-china-biotech-names-4fcfe264207382d9 2026-09-21T22:12:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nvidia-qia-backed-iambic-therapeutics-files-for-us-ipo-as-biotech-boom-rolls-on-6bcac29ff06fe76b 2026-09-21T21:41:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-logistics-market-to-reach-usd-194-0-billion-by-2034-at-7-7-cagr-d-405b29a18e79aec5 2026-09-21T21:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-stocks-and-leveraged-etfs-lead-market-d-9c02833c76771b58 2026-09-21T21:28:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/eli-lilly-breaks-ground-on-6-5b-houston-plant-078eb0965183eec9 2026-09-21T21:21:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/dompe-settlement-highlights-doj-continued-scrutiny-of-pharmaceutical-manufacture-433de672942d089b 2026-09-21T21:15:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/iam-ipo-news-small-molecule-biotech-iambic-therapeutics-files-for-a-100-million-3bc12612e27dfbee 2026-09-21T21:10:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/eli-lilly-breaks-ground-on-6-5b-pharmaceutical-factory-in-houston-2f381a479b3555a2 2026-09-21T20:58:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/screening-china-origin-biotech-ip-a-new-u-s-eu-divide-fe79769761ea8dd8 2026-09-21T20:45:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/nvidia-qia-backed-iambic-therapeutics-files-for-us-ipo-as-biotech-boom-rolls-on-4b5e30b480cbde92 2026-09-21T20:38:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/medicus-pfizer-deal-was-not-a-fire-sale-a-strategic-bet-on-de-risked-adc-drug-8e03cd57f1797c93 2026-09-21T20:35:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/buerger-s-disease-clinical-trial-pipeline-gains-momentum-3-91e1bc0bbb6b2bea 2026-09-21T20:24:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-glp-1-shortage-is-over-mass-market-compounding-should-be-too-5d8cd6869a85189b 2026-09-21T20:06:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/eli-lilly-connected-peninsula-company-plots-ipo-as-it-takes-on-eczema-and-more-0871b8e09373ffce 2026-09-21T19:51:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/positive-topline-phase-3-study-results-lumateperone-for-manic-episodes-in-bipola-ea5127591948df34 2026-09-21T19:34:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-teva-why-is-it-back-in-the-spotlight-feca7b108b11fdaf 2026-09-21T19:11:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/cphi-milan-leadership-summit-returns-with-supply-chain-focus-543b72ef7ec0a6e6 2026-09-21T19:06:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/faq-how-the-generous-model-applies-mfn-pricing-to-medicaid-3108639fbd284b85 2026-09-21T19:04:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/new-analyses-of-hlp003-for-the-adjunctive-treatment-of-mdd-610c32551287df6e 2026-09-21T19:04:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-forms-ai-powered-drug-discovery-partnership-with-iambic-pharmexec-7df1eac9f5ddbb27 2026-09-21T18:57:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-updates-regulations-to-expand-alternatives-to-animal-testing-in-drug-develop-0ab1dcb84feb442a 2026-09-21T18:33:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/s2s-china-selects-10-biotech-finalists-to-pitch-global-investors-at-westlake-uni-cc798694b80a8b1b 2026-09-21T18:33:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/sec-fda-information-sharing-mou-implications-for-pharma-and-biotech-f12ad8cd85d5f095 2026-09-21T18:24:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmosa-biopharm-s-inhaled-drug-l608-wins-fda-approval-for-phase-2-trial-shares-623a9af03fd0b72d 2026-09-21T18:23:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/life-sciences-real-estate-trends-what-to-expect-3bd7b4d3a44b9c76 2026-09-21T18:05:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-stocks-to-watch-and-pharma-industry-news-72f24107382921a8 2026-09-21T17:49:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-updates-regulations-to-advance-innovative-alternatives-to-animal-testing-2a5644680d80e2c1 2026-09-21T17:14:21.000Z weekly 0.7